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5Diabetes:  
A chronic disease where blood
glucose is too high, either
because insulin is not produced
or is insufficient
Symptoms: 
Tiredness, weight loss, increased
thirst, passing a lot of urine,
blurred vision
Complications: 
Serious complications can result
from elevated blood glucose,
some of which are illustrated here.
However these are largely
preventable, and can be delayed
with early diagnosis and effective
treatment
Effective
treatment
can reduce
costly diabetes
complications
by up to 50%
Heart Attack
Risk:
Increased by 300%, and
heart disease is up to
4 times as likely
Effective treatment:
Leads to a reduction in
heart failure of over 50%
Stroke
Risk:
Up to 4 times as likely
Effective treatment:
Reduces strokes by more
than a third
Amputation
Risk:
15% develop foot ulcers
and up to 15% of these need
amputations. Most common
cause of non-traumatic
lower-limb amputations
Effective treatment:
Reduces the number of
amputations and effective
education reduces the
number of foot ulcers
Total Kidney Failure
Risk:
3 times as likely as in the
normal population. About
30% of type 2 patients have
renal disease
Effective treatment:
Reduces the causes of kidney
failure by more than a third
Blindness
Risk:
Single largest cause of new
cases of adult blindness in
the UK.  Nearly all those with
type 1 diabetes experience
minor retinal damage within
20 years, as do 60% of those
with type 2
Effective treatment:
Reduces serious deterioration
by more than a third
Figure 1 | Effective treatment can reduce costly diabetes complications by up to 50%
Sources: UKPDS (5, 6) and National Diabetes Audit (7)
Effective treatment can reduce costly diabetes complications by up to 50%
Source: Diabetes: finding excellence? The MODEL group.
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further development of pharmacy based care as a cost 
effective part of the support available to people with 
diabetes and to highlight the importance of pharmaceutical 
innovation alongside that of facilitating relevant forms of 
health behaviour change.
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Summary and Recommendations 
The number of people with diagnosed diabetes (as defined by their blood glucose 
levels) has doubled in the UK in the last decade, to a total of over 2.5 million. In 
addition there are likely to be 500,000 people with undiagnosed diabetes. However, 
worldwide most cases of diabetes already occur in Asia.
In developed countries diabetes and its consequences account for 5-10 per cent of health 
spending. This represents in excess of 0.5 per cent of global GDP. In the UK such data 
imply an annual expenditure of over £7 billion. About £1 in every £10 spent by the 
NHS on diabetes is accounted for by medicine costs, including all forms of insulin.
The rising prevalence of diabetes is linked to obesity, population ageing and better 
case recording. The average Briton now has a 10-20 per cent life-time chance of 
being diagnosed as having diabetes. Those most at risk in the South Asian and other 
communities are least likely to understand its causes. Effective prevention and better 
treatment are both urgent priorities. More effort should be made to enhance public 
understanding of diabetes.
Pharmacists have an important future role to play in delivering care to people at 
risk of – and with – diabetes. This will in part involve conducting health checks 
to identify risk factors and find early stage cases. Community pharmacists should 
support lifestyle changes through, for instance, weight loss, smoking cessation 
and self care programmes, and help individuals and families with diabetes to use 
medicines more effectively. 
Type 2 diabetes accounts for 80 per cent or more of all cases. It is a progressive 
condition. If not treated appropriately via lifestyle changes (such as taking more 
exercise) and medicines it leads to disability and premature death. Having diabetes 
multiplies the harm caused by vascular disease risk factors such as smoking, raised 
cholesterol levels and high blood pressure. 
Medicines such as statins and antihypertensives protect people with diabetes from 
heart attacks, strokes and other vascular diseases. Established anti-diabetic treatments 
help to lower blood sugar levels and also prevent harm. 
New treatments with mechanisms of action such as those relating to the role of the 
intestinal peptide GLP-1 could have extended protective impacts. Bariatric (‘stomach 
stapling’) surgery is appropriate for treating gross obesity and may also slow or even 
reverse the progression of type 2 diabetes.
Approaching 400,000 people in the UK have type 1 diabetes, in which individuals’ 
own defence cells destroy their pancreases. This condition seems most likely to affect 
people of European racial origin. Those living with it need insulin therapy.
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Ultimately, stem cell based or allied techniques should lead to treatments that 
regenerate lost pancreatic tissues. But more immediate advances are likely to 
involve the development of ‘artificial pancreases’, using implantable blood glucose 
monitoring devices. Implantable glucose monitors and other forms of ‘artificial 
pancreas’ technology could worldwide improve the quality of life of millions of 
insulin users in the coming five to ten years.
Modern human insulin analogues are designed to help people improve their 
blood glucose control. There is evidence that they can help individuals to improve 
their quality of life and protect against unpleasant and potentially hazardous 
hypoglycaemic events. In future new generations of inhaled and oral insulins will 
further help to improve health outcomes and increase service user satisfaction.
Little more than one per cent (and less in the case of children) of British people 
with type 1 diabetes presently use insulin pumps for the routine management of 
their condition. The equivalent proportions in countries such as France, Sweden, 
Holland, Germany and the US are in the range of 10-20 per cent. This situation 
requires review in the light of present advances. 
In England innovations such as the Quality and Outcomes Framework in the 2004 
GPs’ contract have led to important service improvements. Yet there is a need to 
further improve diabetes care and outcomes. The 2008 white paper Pharmacy in 
England recommended that pharmacists should extend the services they provide for 
diabetes prevention, case finding and treatment. More care for people with diabetes 
should be delivered in primary care settings.
It is important to ensure appropriate patient access to specialists. Increasing 
patient choice of and access to convenient local sources of cost effective support 
is also desirable. NHS remuneration systems should be adapted to promote more 
integrated diabetes care and better joint working between GPs and community 
pharmacists.
Individual and group support and/or ‘therapeutic education’ programmes can help 
people to adopt healthier lifestyles and take medicines more effectively. They are 
potentially highly cost effective. But to date only one person with diabetes in every 
ten has had access to such services. Their provision should be extended.
Bodies such as The National Institute for Health and Clinical Excellence and its 
equivalents conduct useful work. However, the human and financial costs of delaying 
patient access to useful new therapies for diabetes may prove high. Care should be 
taken to minimise this hazard.
Successful public health improvement will in the twenty first century demand both 
new medicines and health behaviour changes. Pharmacy can combine the delivery 
of both these vital ingredients for the prevention and treatment of diabetes.
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Introduction
The term diabetes refers to a group of complex disorders that 
are primarily defined by a hazardously raised level of blood 
glucose (sugar). This results either from a loss of the body’s 
capacity to produce the hormone insulin, or from reductions 
in the latter’s ability to induce normal glucose uptake by 
muscle cells and organs such as the liver. 
Descriptions of diabetes, at least as a condition characterised 
by increased rates of (abnormally sweet tasting – hence 
mellitus) urination, date back to ancient Egypt and Greece – 
see Box 1. But it is in modern societies that the prevalence of 
the main forms of diabetes has risen to what can be considered 
pandemic levels. Some observers believe that increases in the 
occurrence of diabetes will in future decades cut short the rises 
in life expectancy that have been associated with economic 
development during the twentieth century. 
Diabetes lies at the heart of the nexus of conditions that are 
on occasions referred to as ‘the metabolic syndrome’ (Alberti 
2008a, 2008b). This encompasses traits such as central obesity, 
raised blood pressure and a depressed level of high density 
(cholesterol carrying) lipoprotein. Such factors are intimately 
linked to morbidity and mortality from heart disease and 
other vascular conditions. Diabetes exacerbates the risks 
people have of suffering ‘macro-vascular’ events such as heart 
attacks, and also puts them in danger of developing micro-
vascular damage to organs such as their eyes and kidneys. Its 
complications are a common cause of the lower limbs having 
to be amputated. Because of its serious consequences, diabetes 
care is commonly estimated to account for between five 
and ten per cent of health care costs in the developed world 
(that is, in excess of 0.5 per cent of global GDP), and similar 
proportions of premature disability and death.
Alongside sedentary life styles, and socially influenced habits 
such as tobacco smoking and excessive alcohol intake, a rising 
incidence of diabetes is central to the physical and linked 
mental health challenges confronting populations living in 
conditions of material plenty. Today’s wealth in countries such 
as the US and those of the EU and the growing prosperity of 
people in emergent economies contrasts sharply with the 
relative poverty in which humanity evolved.
Against this background, this report describes recent 
developments in bio-medical, behavioural and social 
understandings of diabetes and how it can be prevented and 
treated. Its most important objectives relate to the further 
development of pharmacy based health care as a cost effective 
part of the overall pattern of support available to people 
with diabetes. This should facilitate a combination of better 
medicines use and positive health related behaviour changes. 
This report also seeks to contribute to wider public and 
professional debate about the nature of diabetes and how 
individuals and communities should respond to the threat 
it represents. It seeks to promote a balanced awareness of the 
fact that although there is no such thing as a ‘mild’ case of 
diabetes – everyone who is diagnosed with any variant of the 
disorder is at raised risk of disability or death – appropriate 
management can significantly reduce the harm that it would 
otherwise cause.1
Box 1. An Outline History of Diabetes 
1550 BC Earliest known record of diabetes. The papyrus 
of the Egyptian physician Hesy-Ra notes polyuria 
(frequent urination) as a symptom. The condition 
was also known in ancient India, although the term 
diabetes itself (meaning to siphon fluid) appears 
first to have been used by the Greek physician 
Appolonius of Memphis in circa 250 BC.
1797 AD Dr John Rollo, surgeon general of the Royal Artillery 
in the British Army, publishes his ‘account of two 
cases of the diabetes mellitus’. Rollo was the first to 
use the term ‘diabetes mellitus’ (meaning honey, 
or sweet tasting) and to make the distinction 
between this and diabetes insipidus, which 
involves frequent but tasteless urination.
1920 Building on German research, the Canadian 
Frederick Banting commences his work on isolating 
insulin (a word first coined in 1915, derived from 
the Latin for island). He conducted research on 
dogs with their pancreases removed.
1921 Insulin extracted by Banting, Best, Macleod and 
Collip. A dog without a pancreas was successfully 
‘treated’.
1922 Insulin first tested on a human. Prior to this point 
there was no treatment for type 1 diabetes – it 
was invariably fatal. 
1955 Amino acid sequence of insulin first described 
Sanger. Metformin became available at around 
this time, as did the first of the Sulphonylurea 
medicines.
1960s Home testing for blood glucose levels in urine 
developed, in order to help people with diabetes 
to achieve better control of their condition.
1970 Blood glucose meters and insulin pumps first 
developed.
1981 First successful transplantation of islet cells.
1983 Biosynthetic human insulin introduced.
1986 Insulin pen delivery systems introduced.
1993 The Diabetes Control and Complications Trial 
(DCCT) reports that the intensive treatment 
of people with type 1 diabetes to keep their 
blood glucose down to near normal levels 
delays the onset and progression of long-term 
complications.
1998 United Kingdom Prospective Diabetes Study 
(UKPDS) reports that good glucose and blood 
pressure control are also important in type 2 
diabetes.
2005 First islet cell transplant operation for an individual 
with Type 1 diabetes that resulted in insulin 
independence.
2006 The initial incretin mimetic is licensed in the UK, 
followed by the first DPP-4 inhibitor medicines 
in 2007.
2008 The number of gene sites known to be associated 
with type 2 diabetes rises to sixteen.
See in addition http://www.jdrf.org.au/publications/
factsheets/the_history_of_diabetes_and_the_search_for_a_
cure.pdf
1  It has in the past been accepted that a diagnosis of type 1 diabetes 
reduces life expectancy by an average of around 20 years, and one 
of type 2 by 10 years. However, there has always been considerable 
variation around these means, and modern advances in treatment 
have considerably improved the prognosis for people living with 
diabetes.
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There is a strong case that diabetes should wherever possible 
be prevented by prudent lifestyle changes. However, this is 
not always possible, even in the case of type 2 (adult onset, or 
what was at one time called non-insulin dependent) diabetes. 
Individuals are not always able to change their responses to 
the environments in which they find themselves. In addition, 
genetically linked and/or other (presently) non-modifiable 
variables are in many instances the main cause of diabetes. In 
these circumstances effective treatment is the only option.
Despite the important progress made in the NHS and other 
health care systems since the 1990s, even more can in future 
be done to ensure full access to services such as screening 
for diabetic retinopathy (which Department of Health data 
indicate was offered to 85 per cent of people with diabetes in 
England in 2007) and group based ‘therapeutic education’. 
Enhanced efforts should be made to promote optimal use of 
anti-diabetic medicines, including both ‘natural’ and modified 
(analogue) forms of insulin. The aim of therapy should (in 
addition to controlling variables such as cholesterol levels) be 
to keep the blood glucose levels of people living with diabetes 
within, as far as is practically possible, a normal spectrum. At 
the same time the incidence of frightening and sometimes 
life threatening hypoglycaemic events should be minimised. 
Dangerously low blood sugar levels are caused by unduly 
high, or long lasting, doses of therapeutic insulin.
There is a growing consensus that nurses, pharmacists, 
doctors and other health professionals should further extend 
their support for people living with diabetes in order to 
facilitate informed personal choice, and the best achievable 
quality of life. For nearly everyone this will involve not just 
controlling biomedical risks but also living as normally as 
possible, with as much freedom from rigid restraints as their 
peers enjoy. Health professionals also need to ensure that 
individuals and groups at special risk – such as pregnant 
women, older health service users with multiple disorders, 
and people with learning disabilities or severe mental health 
problems – receive good care and support. 
Yet even if this is achieved, and communities also become 
better adapted to living with material plenty, presently 
available pharmaceutical and related medical technologies 
cannot – despite the promise their use holds for better health 
outcomes – cure or totally offset the risks of diabetes. For 
this reason, another key message of this study is that efforts 
to deliver existing treatments and manage today’s resources 
should not draw attention away from the importance of 
investing in research for the future. 
Figure 1. Prevalence of Diabetes across the World
Source: WHO (2008)
Accessed at: http://www.who.int/diabetes/facts/en/index/.html [last accessed 20.3.08]
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In the medium to long term there are profound benefits 
to be derived from innovations that will arrest or reverse 
the mechanisms involved in phenomena such as ‘insulin 
resistance’ and the progressive destruction of the insulin 
producing cells of the pancreas. From a global equity 
perspective, for example, it may be noted that although 
type 1 diabetes is currently most likely to occur in children 
and young adults of European ethnicity, white Europeans 
are generally less at risk of type 2 diabetes than are people 
of other racial origin when they are living in conditions of 
material plenty. India already has more people living with 
diabetes than any other country (Figure 1).
Political decisions must partly be driven by relatively short 
term electoral considerations, coupled with a legitimate 
desire to use today’s resources effectively and efficiently. Yet 
responsible health professionals and health sector policy 
makers should be robustly aware of the reality that sustained 
investment in pharmaceutical and other medical research 
will over the coming decades ultimately lead to major new 
gains, which existing forms of care cannot offer. Seen from 
this perspective, spending on recently developed treatments 
like the enhanced insulins and incretin mimetics described in 
this paper is worthwhile not only for its immediate benefits 
for individuals. It offers additional value in as much that it 
represents at a population level a stepping stone to a better 
future, providing not only a scientific but also a financial 
basis for ongoing discovery.
An Evolving Individual and 
Community Threat
Glucose ‘powers’ all higher forms of life. During the process of 
digestion it is derived from food, transferred via the intestines 
into the blood stream, and subsequently delivered to the liver, 
muscles and other parts of the body like fatty tissues and the 
brain. There it is either used to energise reactions, or stored 
in the form of glycogen. The pancreas plays – as is described 
in Figure 2 – a central part in managing this process. When 
blood sugar levels rise it releases insulin. The latter binds to 
receptors on cells throughout the body in order to trigger (via 
a complex cascade of intra-cellular messengers and reactions) 
the uptake of glucose. Against this, when blood sugar levels 
fall a second hormone, glucagon, is secreted by the pancreas. 
This causes the release of additional amounts of glucose from 
organs such as the liver.
In diabetes this regulatory balance is to varying degrees 
impaired. Type 1 diabetes is most commonly the result of 
pancreatic beta cell destruction due to an autoimmune reaction, 
triggered in susceptible individuals by as yet unidentified 
external factors. Although in older children and some adults 
this process may continue for some time before consequences 
of pancreatic beta cell depletion become apparent, the initial 
onset of type 1 diabetes is typically acute. It may, for instance, 
involve an attack of ketoacidosis (Box 2). 
Children, young adults and older individuals who develop 
type 1 diabetes need insulin therapy immediately. By contrast, 
the onset of type 2 diabetes is normally insidious – see Figure 
3. It may take a decade or more from the start of the process 
to when diabetes can be diagnosed and often, although not 
always, many more years or decades before insulin treatment 
is (if ever) required. 
Depending on their genetic endowments and very early 
life experiences, individuals who are exposed to life styles 
Figure 2. The Pancreas and the Insulin Glucagon 
Balance (after the MODEL group 2007)
Typically a random blood glucose test of over 11.1mmol/l 
or a fasting blood glucose level of over 7.0 mmol/l indicates 
an individual has diabetes, although these two measures 
have varying degrees of specificity and sensitivity.
which cause them to put on weight and build up abdominal 
fat tend slowly to become resistant to insulin. That is, for 
a given amount of glucose entering the blood stream the 
pancreas gradually has to produce increased amounts of 
insulin to ensure its appropriate take up by the body’s tissues. 
This means that the average levels of insulin in affected 
individuals’ circulatory systems rise, causing a state known 
as hyperinsulinaemia.
The term insulin resistance was first coined by the British 
physician Professor Sir Harold Himsworth (who after the 
second world war became secretary of the Medical Research 
Council for almost three decades) in the 1930s. Despite the fact 
that several sets of mechanisms have been proposed, its causes 
are not yet fully understood (Stumvoll et al 2005). However, it 
is well established that abdominal adiposity (characterised by 
the build up of cells caused adipocytes, which store energy in 
the form of triaglycerol) is linked to raised levels of free fatty 
acids in the blood plasma. Adipocytes also produce a wide 
range of substances called adipokines and cytokines. These 
molecules influence metabolic, inflammatory and other key 
processes in many parts of the body.2
Becoming ‘fat’ can also (along with ‘ageing’ generally) 
cause people to reduce the amount of exercise they take. 
2  In broad terms type 2 diabetes can therefore in many (but not all) cases 
be seen as being a consequence of long term over- or miss-feeding, 
through which eventually the body’s ability to use glucose and store 
fats normally is overwhelmed. This results in a wide range of deleterious 
consequences. However, from a sociological and pharmaceutical or 
medical care perspective it is important to stress that individuals who 
develop diabetes should not be unfairly stigmatised. Rather, it should 
be understood that their constitutions are such that they are unable 
to live healthily in the society around them.
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This may additionally contribute to problems such as 
insulin insensitivity, because of changes in skeletal muscle 
functioning and mass relative to the rest of the body. Some 
individuals who develop insulin resistance suffer no observed 
ill effects, and may in time return to ‘normal’. Yet others 
eventually lose permanently their ability to make enough 
insulin to meet their rising need for it because they suffer 
progressive pancreatic damage alongside insulin resistance. 
Some commentators believe that hyperinsulinaemia may 
contribute to the latter, and that it can also be a cause of 
raised blood pressure.
The next stage of the typical ‘spiral’ or decline leading to a 
diagnosis of type 2 diabetes shown in Figure 3 is impaired 
glucose tolerance. Because the body cannot produce enough 
insulin to meet ‘peak demands’ after meals, blood sugar levels 
rise above normal thresholds. This may result in further 
pancreatic cell damage and other forms of harm, in part 
because proteins and lipids in the body become glycosylated. 
(That is, complex carbohydrates become attached to them.) 
This engenders micro-vascular disease and also accelerates 
the build up of atheroma in the major blood vessels. Micro-
vascular damage is the result of glycoproteins being formed 
in the walls of small blood vessels, making them both thicker 
and weaker than normal. As already noted, this often affects 
retinal tissue and the kidneys, and can (especially when 
inadequately treated) also cause problems such as neuropathy 
(nerve pain associated with a partial loss of protective myelin 
sheathing) and foot ulcers.
Even at the stage of impaired glucose tolerance, many 
people may – if they change their lifestyles – either recover 
normal functioning, or at least significantly delay the further 
progression of their ‘pre-diabetic’ condition to diagnosable 
diabetes. As discussed in Box 3, this is defined by fasting and/
or post-prandial (after eating) blood glucose levels known to 
be associated with long term harm, as well as with immediate 
symptoms such as excessive urination, thirst, tiredness and 
– in some people at least – mood variations.
Once diabetes is established the task facing affected 
individuals and their health advisors in large part centres on 
managing their blood glucose levels as well as possible, and 
reducing the risks of associated harm to a minimum. But even 
then some interventions – most notably bariatric surgery, 
or ‘stomach stapling’ – appear on occasions to be associated 
with a recovery of normal functioning.
Genetic heritage and the thrifty phenotype
Over and above the conditions encompassed in the types 1 
and 2 diabetes categories, other forms include gestational 
diabetes, and diabetes occurring as a result of pancreatic 
diseases and trauma, conditions such as acromegaly or cystic 
fibrosis, and the side effects of medicines. These last include 
some diuretics, cancer treatments and, some observers 
believe, antipsychotic drugs used to treat people with severe 
mental health problems (Holt 2004). However, in this last 
instance schizophrenia itself might be an independent risk 
factor. Diabetes associated with pregnancy is not considered 
in detail in this paper. Yet it represents a significant global 
maternal and child health problem. The research evidence 
available indicates that women who have acquired either type 
1 or 2 diabetes before pregnancy, or who develop gestational 
diabetes during it, benefit from appropriate anti-diabetic 
treatment. So too do their babies.
The evidence available shows that most forms of diabetes are 
strongly associated with genetic vulnerabilities, albeit that in 
Box 2. The Causes and Complications of 
Diabetes
Type 1 diabetes is in most cases associated with an autoimmune 
response that destroys pancreatic cells responsible for 
producing insulin and other substances involved in glucose 
metabolism. During the 1990s it was hoped that the 
mechanisms responsible would be understood relatively 
quickly, opening the way to prevention. But this has proved 
a more complex task than was at that time anticipated.
Immune responses may also be involved in the pathogenesis 
of type 2 diabetes. In at least a proportion of cases the 
dividing line between the two main types of diabetes could 
be less clear cut than is often assumed. However, a wide 
variety of other causes have been postulated in relation to the 
processes of developing insulin resistance and the subsequent 
loss of pancreatic function described in the main text. These 
include the damaging effects of raised levels of fatty acids, the 
impacts of inflammatory and other cytokines and adipokines, 
glucotoxicity, mitochondrial dysfunctions and the possible 
harm resulting from a build up of amyloid protein deposits 
in the pancreas.
There remains, therefore, an extensive biomedical research 
agenda to be addressed in relation to diabetes. However, this 
is not explored in detail this report. For the purposes of this 
analysis key terms and phenomena associated with diabetes 
and its complications include:
Hypoglycaemia
Hypoglycaemic episodes are often referred to as ‘hypos’. 
These occur as the consequence of blood glucose levels falling 
too low. Symptoms may include sweating, shivering, blurred 
vision, anxiety, confusion, dizziness, difficulty speaking and 
nausea. Hypoglycaemia can be corrected by the intake of 
carbohydrates such as simple sugars. 
Hyperglycaemia
Serious hypergycaemic episodes (‘hypers’, associated with 
very high blood glucose levels and an almost total loss of 
insulin) can if untreated lead on to ketoacidosis, which is life 
threatening. 
Ketoacidosis
Diabetic ketoacidosis is most likely to occur in people with type 
1 diabetes, although it can occur amongst some individuals 
with type 2 diabetes when they are exceptionally stressed. The 
condition can have a rapid onset, and demand emergency 
hospital admission. It is the result of abnormal fat metabolism 
leading to a build up of ketones and blood acidosis. It is the 
most common cause of death in children and adults aged 
under forty with diabetes (Gage et al 2004).
Blood glucose levels
To avoid hyperglycemia and/or hypoglycaemia people with 
diabetes (especially those who require insulin) are advised 
to manage their blood glucose levels within defined target 
ranges. These are typically in the order of 90-130 mg/dL (pre-
prandial, or before eating) and below 180 mg/dL at two hours 
after eating. The normal range for people without diabetes 
is 70-100 mg/dL, or 4 to 6 mmol/L, except in the immediate 
aftermath of a meal.
HbA1c
HbA1c (glycosylatyed haemoglobin) measurements reflect 
average blood glucose levels over 2-3 months. Hence they can 
be used as a longer term condition management guide, and 
to predict complication risks. The target HbA1c concentration 
for people with well controlled diabetes is normally regarded 
as being between 6.5 per cent and 7.5 per cent.
Living with Plenty – Meeting the Challenge of Diabetes 9
The individual 
becomes obese 
– see text
Figure 3. The Development of Diabetes
Box 3. Defining Diabetes and its Treatment
Despite work initiated by the WHO in 1965, there were 
before the late 1970s there no robustly established diagnostic 
criteria for diabetes. But today the 1999 WHO definition is 
widely used. This states that a diagnosis of diabetes should 
be made if the fasting blood glucose level is 7.0 mmol/l or 
more, or a random blood glucose test shows a level of over 
11 mmol/l. In patients who present without symptoms the 
WHO recommends that, in addition to blood glucose tests, 
an oral glucose tolerance test is performed. 
The World Health Organisation has also played a vital role 
in developing international awareness of the importance of 
better diabetes care, perhaps most notably via its part in the 
development of the 1989 St Vincents Declaration. This was 
agreed at the start of a critical period in the development of 
the evidence base underpinning the treatment of diabetes. 
In particular the 1990s witnessed:
•	 The	Diabetes	Control	 and	Complications	 Trial	 (DCCT),	
published in 1993. This US led trial showed that intensive 
therapy (frequent doses and self-adjustment according 
to individual diet and activity) delays the onset and 
progression of long-term complications (retinopathy, 
nephropathy and neuropathy) in subjects with type 1 
diabetes. 
•	 The	United	Kingdom	Prospective	Diabetes	Study	(UKPDS),	
published in 1998. This confirmed that for those with 
type 2 diabetes intensive therapy reduces microvascular 
complications. Good blood pressure control was also 
shown to reduce both microvascular and macrovascular 
complications.
poor living conditions these may in some instances also confer 
benefit. Identical twin studies indicate that in a given social 
and economic environment the degree of concordance for 
type 1 diabetes is in the order of 30-50 per cent. That is, if one 
twin develops the condition, the other has a one in three or 
greater chance of also doing so (Dean and McEntyre 2007).
In the main form of type 2 diabetes the equivalent percentage 
is in the order of 80 per cent. That is, if one identical twin 
develops it, there is a four in five chance of the other so doing. 
It appears that the earlier diabetes develops the higher the rate 
of concordance is likely to be. But awareness of this should 
not obscure the fact that at a population level lifestyle is the 
most important cause of type 2 diabetes. 
The reason for this seeming paradox is that the genetic causes 
of the disorder only become relevant at given thresholds 
of food consumption and physical (in)activity. The risk of 
manifestation also relates to the frequency of eating as well as 
to the gross amounts of protein, fat and carbohydrate ingested 
by an individual or population. This is because the burden 
placed on the pancreas and the body as a whole is increased 
by snacking between meals on the one hand, and failing to 
spread food intake prudently over the day on the other.
Broad questions which current knowledge of the genetics 
of diabetes raises include ‘might (as was in the past the case 
with polio) a factor such as delayed exposure to certain antigens 
be responsible for high and still climbing incidence rates of type I 
diabetes in affluent countries like Finland and the UK?’ and ‘to 
what extent are reports of a rising incidence of type 2 diabetes 
in British children and young adults a function of greater ethnic 
diversity?’. The latter concern has potentially important 
implications for the design of public health programmes.
Healthy individual with 
a vulnerable genetic 
heritage and a life style 
characterised by limited 
exercise and high food 
intake
Impaired glucose tolerance 
results from pancreatic damage 
and insulin resistance
Type 2 diabetes thresholds 
reached, oral antihyperglycaemic 
medicines requred
Condition progresses further, 
insulin therapy also required
Type 1 diabetes typically involves 
the rapid destruction of pancreatic 
beta (and other) cells by an auto-
immune response, leading to a 
total loss of insulin production. 
Its causation is in this sense less 
complex than that of type 2 
diabetes, which involves a 
longer pathway and additional 
pathological changes
Insulin level
Possible recovery curve, with 
life style change and pancreatic 
cell regeneration (?)
Type 1 diabetes requires insulin treatment
Insulin resistance requires the 
individual to produce unusually 
high levels of insulin
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Box 4. The Genetics of Diabetes
The great majority of cases of diabetes can be appropriately 
attributed to combinations of both environmental and 
genetic factors. But from a parental perspective it can 
seem vitally important to understand the extent to which 
contracting diabetes is inheritable. Research summarised by 
the American Diabetes Association and Dean and McEntyre 
(2007) indicates that the children of men with type 1 diabetes 
have an approximately 6 per cent (one in seventeen chance) 
of developing the condition. 
The children of women with type 1 diabetes are at less risk. 
If a mother with type 1 diabetes is aged 24 or less there 
appears to be a 4 per cent (one in twenty five) chance of her 
baby developing the condition in later life. But the children 
of women who are 25 or older at the time of birth only 
have a 1 per cent chance of themselves contracting type 1 
diabetes. These risks are approximately doubled if the parents 
concerned developed diabetes before the age of 11, and are 
higher again for children who have both a father and a mother 
with the type 1 condition.
Type 2 diabetes has a stronger genetic basis, but as described 
in the main text its occurrence is also critically influenced by 
life style. Hence it can be difficult in any one case to separate 
‘nature’ as opposed to ‘nurture’. But in general the child of 
a parent with type 2 diabetes has a 14-15 (one in seven) 
per cent risk of developing the condition if the parent was 
diagnosed before the age of 50, but only a 7-8 (circa one in 
thirteen) per cent risk if diabetes becomes manifest later. It 
may be that women are more likely to pass on the type 2 
disorder than men. If both parents have this form of diabetes 
their children have a roughly one in two chance of developing 
it as they mature. 
Box 5. Body Measurements and Type 2 
Diabetes Risk
Obesity (particularly abdominal or central obesity) and type 2 
diabetes have long been known to be linked. In social settings 
such as that of modern Britain a person with a body mass 
index (BMI, defined as weight in kilograms divided by height 
in metres squared) of around 35 has a risk of developing type 
2 diabetes in the order of 20 times that of a person with a 
BMI of 25.
Recently, however, attention has focused on additional 
measurements of waist circumference and waist to hip 
ratio, which may complement use of the BMI. As yet clearly 
defined criteria have not been established, but waist to hip 
ratios of more than 1:1 in men and 0.8:1 in women can be 
taken as indicators of increased risk. Factors such as height 
and ethnicity may need to taken further into account. But is 
presently accepted that a waist size of 37 or more inches in 
males (35 inches in the case of Asian men) and 31.5 inches 
in females should also be regarded as indicative of type 2 
diabetes risks requiring action.
At present rates the projected lifetime incidence for type 2 
diabetes for the average person in Britain (that is, their overall 
risk of being diagnosed diabetic at some point in their life) is 
about 10 per cent, or one in ten. In future this risk could well 
move closer to one in five Yet the lifetime incidence of this 
condition amongst members of the South Asian community 
living in the UK may already be as high as 30-50 per cent, 
or between one in three and one in two. Figure 4 presents 
additional data relating to the issue of ethnicity and diabetes 
related health risks.
Recent research has increased the number of individual 
genes known to be associated with the incidence of diabetes. 
For example, in 2006 an Icelandic group identified a gene 
known as TCF7L2, which subsequent UK research confirmed 
is associated with a doubling of type 2 diabetes incidence 
(Diabetes UK 2006). Further, in 2007 the Wellcome Trust Case 
Control Consortium announced that six new chromosomal 
regions had been found to be associated with type 1 
diabetes (Wellcome Trust 2007). This work cast new light on 
links between type 1 diabetes and other disorders such as 
Crohn’s disease, and the interactions that exist between an 
individual’s genetic make up and environmental factors such 
as infections, diet and relatively low levels of vitamin D. 
More recently still, European and US investigators announced 
six further gene associations with type 2 diabetes, two of 
which (HNF1B and JAZF1) also seem to be linked to a raised 
risk of prostate cancer (NHS Knowledge Service 2008). 
Although the practical value of observations such as these is 
yet to be demonstrated, the number of known associations 
between the structure of the genome and the occurrence of 
type 2 diabetes alone grew from three to sixteen the year or 
so between the start of 2007 and the Spring of 2008.
Box 4 contains further information on the genetics of 
diabetes. However, there are two particularly important 
general points to stress for the purposes of this analysis. First, 
most of the genes to date associated with a raised risk diabetes 
appear, as might be expected, to be related to the formation 
and durability of pancreatic beta cells and variations in 
glucose metabolism. As genetic science advances it should 
become possible to give increasing numbers of people a 
more precise idea of their chances of developing diabetes, 
or precursor states such as insulin resistance and low-level 
impaired glucose tolerance. It should also become possible to 
provide greater insight into of the types of drug that will help 
particular individuals mitigate their risk of serious illness. 
The second point is that an enhanced understanding of 
the genetics of diabetes will also lead to much improved 
understanding of the ways in which environmental factors 
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are associated with the disorder, and how public health 
measures and behavioural changes can most effectively 
protect populations, families and individuals. In this context 
phenotypical rather genotypical variations may often be 
critically important. 
For instance, the ‘thrifty phenotype’ hypothesis suggests 
that poor nutrition before birth and in very early life leads 
to permanent changes in glucose-insulin metabolism that 
subsequently promote type 2 diabetes and other ‘metabolic 
syndrome’ spectrum conditions. The risk of the latter 
occurring is especially great when affected subjects are 
subsequently exposed to relative plenty (Hales and Barker 
2001). Postulated causal mechanisms range from impaired 
pancreatic development in early life to ‘epigenetic’ variations, 
linked to differing patterns of gene expression.
This raises the possibility that, both nationally and on a 
global basis, the current ‘diabetes pandemic’ should be 
approached as a social developmental issue. This in turn 
implies positive as well as negative dimensions, in that the 
social and environmental processes that ‘cause’ diabetes at a 
population level can be seen as being intimately linked with 
progress away from deprivation towards conditions of greater 
security and longevity.
Epidemiological trends
Figures 5a and 5b are based on information produced by the 
US Centers for Disease Control and Prevention. This agency 
holds the most comprehensive epidemiological data on 
obesity available for any population. They show that while 
in 1990 no US state had a prevalence of obesity (defined as 
having a body mass index of 30 or over) of 15 per cent or 
more, by 2006 only four states had a recorded level of under 
20 per cent.
Currently available statistics indicate that although British 
obesity rates are presently below US levels they are above 
the published OECD average levels (Figure 6). Its prevalence 
could amongst adults reach a figure of around 30 per cent 
by 2010 (Department of Health 2006). The reasons why UK 
countries such as England appear to have obesity rates two 
to three times the levels recorded in nations like France, 
Italy and Switzerland are not fully understood. But in 
addition to data quality issues, relevant factors may include 
social factors affecting not only the amounts eaten, but the 
structure and duration of meals and habits such as between 
meal snacking. 
Put simply, strong ‘work ethics’ and relatively long working 
hours may sometimes cause diabetes to develop as a result of 
too pressured a life style, rather than a ‘lazy’ one. The relative 
cultural poverty of manual workers and other less advantaged 
groups in countries such as Britain and the US might help 
to explain not only high obesity rates, but also the fact that 
the UK has higher rates of type 2 diabetes than many other 
western European nations, combined (until recently at least) 
with poor statistics for treatment outcomes such as blood 
glucose control.
Figure 7 and Box 5 highlight further the robust correlation 
between body mass index measures and the risk of developing 
diabetes. This has been confirmed by many different studies 
(Wild and Byrne 2006). Estimates of the prevalence of diabetes 
vary between sources, not least because the age specific 
incidence of the condition is rising and the proportion of 
older people in the population is also increasing.3 The new 
general practice contract introduced in 2004 has also led to 
considerable improvements in case recording. 
However, it can be fairly confidently estimated that there are 
currently between 2.5 and 3 million people in the UK who are 
living with diabetes (that is, about five per cent of the total 
population), of whom in the order of 85 per cent have the 
main form of type 2 diabetes. Adjusting for age, some 6 per 
cent of men living in households with the lowest 40 per cent 
of incomes had diagnosed diabetes in 2003, as opposed to a 
little under 3 per living in households with the highest 40 
per cent of incomes. The equivalent proportions for women 
were 4 per cent and 2 per cent (BHF 2008).
The number of children and adults with type 1 is in the 
order of 400,000 in the UK as a whole. It is probable that 
there are still a signficantly higher number of people who 
have blood glucose levels that have entered the diabetic 
range, but have not as yet been diagnosed. Figures 8a and 8b 
(derived from research undertaken in Wales in the late 1990s 
– Harvey et al 2002) underline the fact that the structures 
of the populations affected by types 1 and 2 diabetes differ 
radically. The prevalence of type 2 diabetes rises consistently 
with age, while that of type 1 declines from later middle life 
onwards. Improved survival rates will to an extent modify 
the age related pattern to date observed in people with type 
1 diabetes. But even so these contrasting distributions will 
remain a strong epidemiological differentiator between the 
two main forms of diabetic disorder.
A ‘diabetic transition?’
The processes of demographic and epidemiological transition 
as they relate to the emergence of ‘modern’ health care 
systems on the one hand, and lifestyle related problems 
such as tobacco smoking on the other, have been described 
in previous School of Pharmacy health policy papers and 
publications. (See, for example, Brock et al 2007, Taylor 
and Bury 2007.) But for the purposes of this report Figure 
9 links in the UK context concepts such as demographic 
and care transition to the presently growing challenge of 
diabetes in both the mature industrialised nations and in 
emergent economies like those of China and India. Important 
observations include:
•	 corrected	for	population	ageing,	vascular	disease	
death rates in Britain have fallen consistently over 
the past 50 years, regardless of governmental changes 
and particular health policy initiatives. Despite the 
concerns of some commentators, it may well be 
that even if rates of (in particular central) obesity 
continue to increase in coming decades, advances in 
pharmaceutically based treatment will ensure that 
age standardised mortality rates continue to decline. 
Yet even if this proves to be the case, a fundamental 
challenge that health care systems in settings such as 
western Europe will inevitably be that of stemming 
increasing volumes of diabetes and wider metabolic 
syndrome related disability, both to extend productive 
working lives and reduce long term care costs;
•	 diabetes	is	now	being	diagnosed	more	frequently	in	
countries such as India. Yet the problems health care 
policy makers face in the emergent economy context 
are still in many respects radically different from those 
of ‘post transitional’ settings such as the UK. In India, 
3  It may be estimated that around 40 per cent of the underlying diabetes 
prevalence increase in this country is associated with population 
ageing, and that the remainder is associated with increased obesity 
rates. (See, for example, YHPHO 2008.)
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Figure 6. Adult Obesity – England and Selected OECD Countries
Figure 7. Body Mass Index and Relative Risk for 
Type 2 Diabetes
have far greater access to health related knowledge 
than ever before. Such trends are now changing the 
social status and roles of health professionals in the 
mature (or post) industrial economies and creating 
new needs for self care support to be delivered where 
possible in normal community settings;
•	 the	fact	that,	richer,	socially	advantaged,	people	in	
Britain have a reduced risk of diabetes could suggest 
that sustained economic development will in time 
lead virtually everyone to choose an optimally 
healthy life style. If ‘diabetic transition’ were a 
naturally self limiting development process, the task 
for health promotion and care agencies could be 
regarded as simply supporting an elective process of 
adaptation. Their role in this scenario is simply to help 
communities adjust to living with plenty as quickly as 
possible. Against this, however, research such as that 
indicating that people of all levels of wealth in the 
US have a higher risk of premature death than their 
equivalents in Britain (Marmot 2007) might indicate 
that health promoting social change is not inevitable. 
That is, in some settings greater wealth and more 
choice may not ‘naturally’ result in better health.
In practice substantial sections of the twenty first century UK 
population will continue to develop type 2 diabetes, regardless 
of attempts to ‘educate’ or ‘enable’ them into choosing healthy 
life styles. If this proves to be so it will present a complex 
ethical and political, as well as practical, challenge for health 
professionals working to reduce diabetes and allied metabolic 
syndrome related harm. Resolving this might ultimately 
demand that future disease prevention programmes should be 
more explicitly focused on pharmaceutical and other health 
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for instance, diabetes is likely to be linked to increasing 
wealth and education rather than relative poverty. 
Worldwide, the majority of the population is more 
educated than it was a century or so ago, and people 
Source: Wild and Byrne (2006)
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Figure 8a. Age and Gender Specific Prevalence of Type I Diabetes (data from research in Wales, 1990s)
Figure 8b. Age and Gender Specific Prevalence of Type 2 Diabetes (data from research in Wales, 1990s)
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product or service marketing based strategies than is presently 
the case. But the view taken here is that medium to long term 
public health improvements in post transitional societies will 
primarily stem from voluntary life style changes backed by 
democratically agreed legislative action, coupled secondarily 
with the professionally supported – yet increasingly personally 
controlled – use of more effective medicines.
Current Approaches to 
Prevention and Treatment
Recent research suggests that it may be possible to prevent 
the onset of type 1 diabetes by ‘vaccinating’ those at risk 
with doses of insulin, administered nasally or via other 
routes (George Institute 2008). In future, as the aetiology of 
this form of diabetes becomes more specifically understood, 
immunologically based strategies aimed at its primary 
prevention may prove safe and effective. But for the moment 
this is not the case. There is currently no known way of 
preventing type 1 diabetes.
However, the occurrence of type 2 diabetes is clearly in large 
part a function of population obesity and (in)activity rates. 
The primary prevention of this condition via interventions 
aimed at promoting lifestyle changes is both possible and 
potentially cost effective. There is, for instance, a growing 
body of evidence stemming from sources such as the European 
Prospective Investigation of Cancer (EPIC) and the studies 
associated with it (one element of which has involved a series 
of linked lifestyle investigations conducted amongst 30,000 
people in Norfolk) indicating that relatively modest changes 
in diet and exercise result in life expectancy gains of up to 
a decade. This benefit appears in large part to stem from 
reduced diabetes related risks. (See, for example, Khaw et al 
2001, Myint et al 2007). This is conclusion is consistent with 
a considerable volume of US research (Perry 2002).
Even small increases in observed vitamin C (ascorbic acid) 
levels in the blood plasma (equivalent on average to a raised 
consumption of fruit and vegetables of only 50 grammes a 
day) have been linked to a 20 per cent reduction in all cause 
mortality. Further, even within the ‘normal’ spectrum, blood 
glucose levels are directly correlated with coronary heart 
disease incidence rates. (Stroke incidence, by contrast, appears 
to increase in a non-linear manner as HbA1c levels rise above 
7 per cent.) UK investigators have also reported that just 30 
minutes of recreational physical activity a day is associated 
with a 10 to 20 per cent reduction in mortality amongst people 
with a sedentary life style.
But attractive though the idea of preventing the occurrence 
of obesity and conditions like type 2 diabetes by modest 
life style changes most certainly is, the barriers to achieving 
this should not be underestimated (Wareham 2008). The 
work of Kinmonth et al (2008) illustrates this reality. They 
recruited 365 people in Norfolk who had a family history 
of type 2 diabetes, and were thus at high risk of developing 
the condition. A proportion were directly exposed to a 
sophisticated, psychological theory based, intervention aimed 
at increasing their physical activity. The remainder received 
either telephone support, or merely an advice leaflet. After 
a year there were no significant differences in activity levels 
amongst the members of these different groups. The authors 
concluded that PCTs and health care providers should be 
cautious about funding services which seek to promote 
individual health behaviour changes.
Technical aspects of this study have been questioned by some 
commentators. Yet it appears to have been of high quality. It 
may also be claimed that the full value of interventions aimed 
at facilitating health behaviour changes cannot be determined 
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via ‘once-off’ trials. From a sociological perspective this is 
true. If, for instance, people’s actions are in reality determined 
more by contextual factors than they are by consciously 
experienced thoughts and intentions, investments in health 
education and literacy may take a generation or more before 
a societal ‘tipping point’ is reached. 
Developments in the area of smoking cessation policy and 
practice reflect this last point. It can thus be argued in the 
context of both obesity and diabetes prevention (and indeed 
in the use of relevant forms of biomedical treatment) that 
investments in logically coherent, constructively intended and 
affordable public health and health promotion programmes 
should not necessarily be curtailed simply because of a lack 
of direct evidence of effectiveness. Rational extrapolation 
from the social and epidemiological experiences of countries 
such as Finland (see, for instance, Tuomilehto et al 2001, 
Lindstrom et al 2004) indicates that both personal support 
and more broadly oriented public health interventions can 
have complementary, and potentially vital, roles to play in 
the primary prevention of type 2 diabetes. 
But at the same time awareness of this should not be permitted 
to draw attention away from the already proven benefits of the 
secondary and tertiary prevention of diabetes and its sequelae. 
This involves early stage detection and oral pharmaceutical 
treatment where possible and later stage surgical and insulin 
based and other oral and injectable interventions when 
necessary. Nor should a desire for behavioural change per 
se obscure the fact that the rational use of safe and effective 
medicines, like those designed to inhibit fat absorption, can 
open the way to weight reductions that will in turn contribute 
to the primary prevention of diabetes. 
The latter does not have to be achieved by behavioural change 
alone (Box 6). Similarly, the primary prevention of conditions 
associated with diabetes, such as CHD and kidney damage, 
can be achieved by means other than diabetes prevention. 
In the latter case the appropriate use of medicines such as 
statins (to control hyperlipidaemia – Reckless 2006) and anti-
hypertensives such as ACE antagonists has fundamentally 
changed not only the outcomes but also the economics of 
diabetes care in the last two decades.
Box 6. Obesity Reduction Programmes
The link between (central) obesity and type 2 diabetes 
incidence has led to increasing interest in the provision 
of obesity reduction programmes. Many trials have taken 
place. Examples of different types of initiative include 
intensive courses in weight loss and waist reduction, group 
and individual counselling programmes, peer-led weight 
loss approaches, exercise programmes with or without 
dietary modification elements, school based approaches and 
numerous health professional led reduction programmes. 
However, the success rates achieved by behaviour change 
programmes alone appear to be relatively limited. There 
appears, therefore, from a public health perspective be a 
good case for combining pharmacological approaches with 
other forms of intervention aimed at BMI reduction, as and 
when this can be shown to help achieve more substantive and 
sustained outcomes than would otherwise be possible.
Early stage detection and treatment
There has been much debate in the UK and elsewhere about 
the value of population wide screening for conditions such 
as diabetes, hypertension and hypercholesterolaemia (Stolk 
2007). Some commentators have argued that such programmes 
are not cost effective, could cause needless anxiety amongst 
vulnerable individuals, and would needlessly increase GPs’ 
and other doctors’ workloads. 
It has in the past been suggested that within the NHS 
an increased emphasis on risk factor identification and 
management would attract resources and doctors attention 
away from the most serious (or ‘deserving’) cases, towards 
the ‘worried well’. Typically, conservatives in this arena have 
favoured opportunistic screening amongst subjects identified 
as being at raised risk, coupled with the intensive treatment 
of people who have, for instance, suffered an initial heart 
attack.
Against this, some (but not all) patient advocates and 
private sector service providers have argued that public 
interests would be well served by more pro-active population 
wide risk and case finding approaches, that encourage all 
adults to ‘know their numbers’ (including fasting glucose 
and cholesterol levels, blood pressures, BMIs and waist 
measurements) and plan actively throughout life to maintain 
the best possible health. The critics of conservative screening 
and testing strategies argue that they stem from paternalistic 
attitudes that exaggerate the risk of causing harmful anxiety 
and could cost lives by inhibiting the development of self 
care motivation and skills. In reality, proponents of this view 
argue, the available evidence suggests that the population is 
more at risk from health risk related indifference than anxiety 
– see, for instance, Eborall et al (2007) 
Advocates of extended access to screening or checks for 
vascular/metabolic syndrome spectrum disorders and risk 
factors may also point out that about 25 per cent of all first 
heart attacks are fatal. Similarly, some forms of disability are 
also irreversible once they have occurred. Recent government 
policy announcements contained in documents such as 
Putting Prevention First (Department of Health 2008b) and 
the 2008 pharmacy White Paper Pharmacy in England (Cmnd 
7341) may appear to offer a resolution to this dilemma in the 
English NHS context. 
The vascular risk assessment model outlined in Figure 
10 represents a pragmatic, systematically structured, way 
forward to improving the identification of early stage disease 
(including diabetes and its precursor states) throughout 
the population. Similar approaches are being developed 
in Scotland, Wales and Northern Ireland. Initial modelling 
indicates that when applied to the overall UK population 
over 40 years of age, such a screening strategy could lead 
annually to around 30,000 cases of diabetes and related organ 
damage being identified earlier than would otherwise have 
been the case, and prevent around 12,000 heart attacks and 
strokes. This could in turn avoid in the order of 2,500 or more 
premature deaths each year.
Experience in the smoking cessation context has demonstrated 
that community pharmacists can successfully deliver 
interventions in a field in which, however important it may be 
in individual and public health terms, a significant proportion 
of doctors have not wished to work. Seen positively, future 
developments in health check provision in pharmacies 
could help protect GPs and their nursing colleagues from 
unnecessary work, and allow them to focus on those cases 
where their unique primary medical care expertise is most 
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Table 1. The main types of anti-diabetic medicine
Class of drug Examples and actions
Biguanides The only drug in this class used to treat diabetes is metformin, which can inhibit the release of glucose 
from the liver and make muscle cells more sensitive to insulin (see text). It therefore enhances the 
effects of insulin being produced naturally. It is possible that treatments with this mode of action 
might prove of value in treating ‘pre-diabetes’, as well as the established type 2 condition.
Sulphonylureas Medicines in this relatively large class (the first of which were also marketed in the 1950s) include 
tolbutamide and glimepiride. They have differing durations of action, but all stimulate the pancreas to 
secrete more insulin. Medicines in this class can cause hypoglycaemia and their use is also associated 
with weight gain.
Alpha-glucosidase 
inhibitors
Acarbose is an example of this class of medicine, which slow the digestion of carbohydrates and so 
help to reduce post prandial blood glucose levels. From a consumer perspective these medicines 
can cause flatulence. 
Meglitinides Medicines of this type include repaglinide and nateglinide. Like the sulphonylurias, they stimulate 
the pancreas to secrete more insulin but via a different mechanism.
Thiazolidinediones Products in this category are sometimes collectively referred as glitazones. They affect adipocyte 
differentiation and reduce insulin resistance. Examples include rosiglitazone and pioglitazone. 
NICE has recommended that the use of these medicines (which were first introduced at the end 
of the 1990s) be reserved for people with diabetes who are unable to tolerate metformin and a 
sulphonylurea in combination and for patients for whom these drugs are contra-indicated (see text). 
New pharmaceuticals with related modes of action are currently being developed.
Incretin mimetics See text and Box 7. Exanitide, the first drug in this class, works by acting on receptors for the naturally 
occurring hormone glucagon-like peptide 1. Futher products in this class are being developed in the 
hope that trials will show that they will offer enhanced benefits to people with diabetes.
DPP 4 inhibitors The medicines sitagliptin and vildagliptin prevent the breakdown of naturally produced GLP-1. This 
class of drugs was first marketed in 2006, and unlike exanitide are taken orally. However, they do 
not offer all its benefits.
Amylin analogues The amylin analogue pramlintide acetate was first marketed in 2005. Amylin is produced in the pancreas 
as well as the brain, and helps to regulate glucose metabolism via affects such as limiting glucagon 
secretion. This medicine is indicated for the treatment of both type 1 and type 2 diabetes.
Insulins Pharmaceutical insulins of all types replace directly the naturally produced hormone and permit the 
survival of those unable to produce it themselves. Their use in type 1 diabetes is therefore vital. In 
type 2 diabetes there is normally more choice as to when a person starts to use these medicines. 
Some may fear doing so, even though the timely commencement of insulin therapy can be beneficial. 
Modern insulins permit physiologically appropriate treatment regimens, combining precise blood 
sugar control with high levels of treatment user behavioural freedom. Presently only injectable forms 
of insulin are available, although work is continuing on orally active and other alternatives.
required. (For an extended discussion of NHS Lifecheck and 
vascular disease check provision issues see Newbould and 
Taylor 2008.) This ought in turn to allow specialists working 
in secondary and tertiary settings to focus their efforts more 
appropriately on individuals with acute and complex care 
requirements, albeit that even within the medical profession 
there has at times been intense debate as to what this should 
in practice imply (Keen 2005). 
Medicines for people with diabetes
As their name indicates, anti-hyperglycaemic medicines work 
to lower blood glucose levels in a variety of complementary 
ways (Table 1). As a rule, they require the pancreas to be 
producing a reasonable level of ‘natural’ insulin. Some, such 
as Sulphonylureas like tolbutamide and Meglitinides like 
repaglinide, augment the latter by enhancing insulin secretion 
for given periods of time. Others, such as pioglitazone and 
rosiglitazone, bind to receptor cells inside cell nuclei and 
stimulate the uptake of glucose and fatty acids into adipocytes 
(abdominal fat cells). 
They also help to generate increased numbers of adipocytes. 
This normally leads to weight gain. But it also beneficially 
reduces insulin resistance in the muscles by cutting fatty acid 
levels in the musclature. Despite the controversy which has 
on occasions been associated with this class of medicines, 
their appropriate use can confer significant benefits on people 
with diabetes.
In the case of individuals who have both diabetes and an 
additional diagnosis of heart failure (which is not uncommon), 
a recent systematic review found that of the currently well 
established antidiabetic agents only metformin can confer 
benefit while also being free of any association with harm 
(Eurich et al 2008). Metformin belongs to a class called the 
Biguanides and is related to a traditional medicine called 
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Figure 10. Vascular Risk Assessment Programme
galega officinalis, or goat’s rue. This was used in the treatment 
of diabetes for several centuries before the modern era. 
Metformin, which was originally developed in France, has 
now been continuously available in Britain (despite being 
withdrawn by the FDA from the US market for an extended 
period, probably at some cost in terms of American lives) 
for over fifty years. It reduces the hepatic output of glucose 
and also increases the latter’s uptake by the skeletal muscles, 
through reducing insulin resistance. It is only relatively 
recently that this medicine’s mode of action has been 
elucidated (Munday 2008). It activates within muscle cells an 
enzyme called AMPK (AMP activated protein kinase). 
This has a range of important effects relating to glucose 
metabolism and within the brain to appetite regulation. It is 
now understood that taking metformin, the contra-indications 
to which have in the past have been overstated (Jones et al 
2003), has effects that are similar to the body’s natural response 
to exercise. Such observations suggest that this drug, or new 
medicines with the same mode of action, may in future have 
more to offer in terms of either being used in association 
with life style interventions to prevent or slow ‘pre-diabetes’ 
progression, or to treat more effectively established diabetes. 
However, it should be stressed that as yet no form of ‘pre-
diabetes’ pharmaceutical intervention has conclusively been 
shown to prevent diabetes expression (Alberti 2008a).
The injectable incretin mimetic exenatide is an example of a 
more recently marketed product that may also prove to have 
important advantages in treating and slowing or perhaps 
even preventing the progression of type 2 diabetes and/or its 
precursers. It acts in a manner like that of a substance made 
in human intestinal mucosa called glucagon-like peptide 1 
(GLP-1, see Box 7). Similarly dipeptidyl 4 protease (DPP IV) 
inhibitors prevent the breakdown of GLP-1, the production 
of which is known to be impaired in people developing and 
who have type 2 diabetes. These products have significant 
value and the advantage of being taken orally, although 
they do not permit the build up of levels of the hormone 
sufficient to achieve the overall benefit associated with 
exanitide use.
Such developments underline the important potential of 
new pharmaceuticals to contribute more to controlling the 
diabetes pandemic. However, as is normally the case with any 
class of drug, the use of medicines to this end is not without 
critics and controversies. In addition to the general point that 
a reliance on ‘pills’ should not be allowed to obscure the vital 
benefits of, for example, regular daily walking (Gray 2008) 
and other forms of moderate exercise such as swimming, 
these include:
•	 Is attempting to prevent diabetes with 
‘pills’ inherently counterproductive? Some 
authorities (such as Montori et al 2007) have argued 
against the use of medicines such as rosiglitazone (as 
recently explored via the DREAM trial – DREAM Trial 
Investigators 2006) to delay or possibly prevent the 
onset of diagnosed diabetes. (See also Tuomilehto and 
Wareham 2006). Beyond specific detail, Montori et al 
point out that the encouragement of such strategies 
may be motivated by commercial greed rather than 
medical altruism. However, provided the costs (and 
risks in context where perhaps more than a half of 
users will not in any case progress to full diabetes) as 
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against the benefits of pharmaceutical interventions are 
measured and evaluated with integrity against other 
possible social, economic, psychological and medical 
options, it would be hard to justify a claim that it is 
necessarily wrong to try to delay the onset of diabetes 
with medicines as opposed to any other form of action. 
Indeed, ideologically based beliefs to this effect could 
damage public interests. 
•	 Is a ‘glucocentric’ approach to diabetes 
treatment counterproductive? Following findings 
such as those of the UKPDS people with all forms of 
diabetes are being treated more intensively than was so 
in the past. This, coupled with increased identification 
of the condition, has driven up treatment costs and 
exposed more patients to the threat of hypoglycaemic 
events and other possible side effects. Some 
commentators, particularly following concerns raised 
early in 2008 by the halting of part of a trial known as 
ACCORD (evaluating the benefits of intensive glucose 
control), have suggested that very tight glucose control 
strategies may neither be financially nor therapeutically 
desirable (Yudkin 2008). 
It is unquestionably the case that a concern for managing 
blood glucose levels should not blind either professionals 
or people with diabetes themselves to the benefits of other 
interventions, such as using statins and appropriate anti-
hypertensives. However, there is firm evidence that even 
today many people with diabetes are being placed, or are 
placing themselves, at needlessly high risk of premature death 
or disability through a failure to control their blood glucose 
levels as well as is possible. 
Theoretical concerns that very intensive type 2 treatment 
programmes combining high level insulin use with medicines 
that enhance insulin sensitivity might increase mortality 
deserve due attention. This is not least, from an academic 
perspective, because they raise the possibility that insulin 
resistance could in some contexts have a protective function 
(Home 2008). But the significance of the ACCORD results 
should not be over-emphasised, especially as they have not 
as yet been fully published. For practical purposes one of 
the major problems facing people with diabetes and the 
health professionals seeking to support them remains that 
of inadequate glucose control, rather than unduly effective 
intervention. The conclusion drawn here is that excessive 
criticism of current therapeutic approaches could undermine 
rather than protect public interests.
Improving insulin treatment
The discovery process leading to the work of Frederick Banting 
and his colleagues in Toronto at the start of the 1920s, and the 
initial treatment of the fourteen year old Leonard Thompson 
with insulin in 1922, is a landmark story of medical and 
pharmaceutical advance. Along with milestone events such 
as the development by Paul Ehrlich and Hata Sahachiro of 
salvarsan for syphilis just over a decade before, it ushered in 
the period of modern therapeutics.
Yet for Thompson (who died at the age of twenty seven, 
and from a patient perspective was arguably the most 
important hero of the insulin discovery story) and others 
with diabetes who were desperately awaiting effective care, 
insulin was at first far from satisfactory as a treatment. 
The inadequately purified calf’s insulin he received caused 
a severe allergic reaction. However, this problem was 
relatively quickly overcome, and the challenge for people 
5  When and if non-invasive or minimally invasive glucose monitoring 
can reliably produce sufficiently accurate readings its potential to 
improve diabetes care should not be ignored. Nor should not the 
utility of appropriately employed urine tests be under-estimated. 
Continuous Glucose Monitoring (CGMS) is a method of following 
blood glucose over time, which may offer the prospect of enhanced 
glycaemic control. However, there is little evidence as yet of this leading 
to HbA1c reductions.
Box 7. Incretin Agonists and Analogues, and 
the Role of Pharmacists in Diabetes Care
It has been known since the 1930s that a number of peptide 
hormones are produced in the small intestine. The most 
important of these appears from a diabetes care perspective 
to be glucagon-like peptide 1 (GLP-1). Research on such 
substances, often referred to as incretins, was first prompted 
by an awareness that taking glucose orally leads to a greater 
release of insulin than does the intravenous injection of 
a similar glucose load. This implies that there is a special 
functional relationship between the gut and the pancreas.
GLP-1 acts in part to slow gastric emptying, so regulating 
glucose intake. GLP-1 may also mediate satiety (the feeling 
of having eaten enough) via direct effects on the brain, and 
reduce the liver’s output of glucose via inhibiting the release 
of glucagon (Gallwitz and Bachmann 2007). In addition it 
increases insulin secretion under hyperglycaemic conditions 
and – some researchers believe – can also preserve or possibly 
even enhance pancreatic beta cell mass. So far the evidence 
for this last is based on animal models. But it has already 
been demonstrated that incretin mimetics (unlike the DPP 4 
inhibitors) can promote weight loss in people with diabetes, 
while at the same time significantly reducing their HbA1c 
levels.
This new class of medicines might therefore have a 
considerable future role to play in the treatment, and perhaps 
the prevention, arrest or delay of type 2 diabetes. Exanitide, 
the first of the incretin mimetics to be marketed, was originally 
found in the saliva of the Gila monster, a venomous North 
American lizard. It binds to the same sites as human GLP-1, but 
is more stable. While the natural human peptide is normally 
destroyed within minutes, this medicine can be injected on 
a twice daily basis.
Current research efforts are aimed at introducing incretin 
mimetics that offer additional advantages. For example, 
exanitide stimulates the production of antibodies in many 
people taking it. This on occasions blocks its therapeutic 
action. It may be that molecules exactly like human GLP-1, 
although modified to make them long lasting in the body, will 
prove less immunogenic and/or capable of administration on 
a once rather than twice daily basis. (To mark this difference, 
some commentators refer to the latter as human GLP-1 
analogues, while calling exanitide a GLP-1 receptor agonist.) 
It is also possible that orally active or possibly inhaled GLP-1 
based medicines will in time be developed.
From a pharmaceutical care viewpoint such illustrative 
possibilities suggest that in the long term treatments based 
on a definitive understanding of the processes leading to 
type 2 diabetes will emerge. Used at a population level as 
public health interventions, such innovations may contribute 
to ending the global diabetes pandemic. More immediately, 
they highlight the availability of a growing range of effective 
treatments for reducing the individual harm caused by 
diabetes, and the potential role of appropriately educated 
and skilled pharmacists in the clinical management of 
diab tes. If pharmaci ts can effectively combine th ir special 
knowledge of established and new m dicines with eff ctive 
health behaviour change competencies they will be able to 
play, alongside doctors, nurses and service users themselves, 
a pivotal twenty first century part in reducing diabetes (and 
more broadly metabolic syndrome) related sickness and 
deaths. Se  main text.
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Figure 11. A schematic illustration of an analogue-based basal-bolus insulin regimen
evidence supporting this view has been criticised by some 
analysts (Richter and Neises 2002). The different properties 
of human and animal insulins meant that some patients 
who were established on the latter encountered difficulties in 
making the transition to human insulin treatment. In some 
cases individuals died from hypoglycaemia. The companies 
producing human insulins (and which gradually withdrew 
from animal insulin supply) have on occasions been blamed 
for such tragedies.
From the late 1990s onwards human insulin analogues have 
become available. These are designed to further enhance the 
control of type 1 diabetes and type 2 cases that cannot be 
treated by oral anti-hyperglycaemics alone. By chemically 
modifying the human insulin molecule its speed and duration 
of action before natural breakdown can be accelerated, and 
extended or shortened. Such innovations are intended to 
enhance the opportunities for people with diabetes to live 
as normally as possible, while keeping their blood glucose 
levels within desired parameters. 
Modern ‘basal bolus’ insulin regimens combine long acting 
and rapid and short acting insulin products, in order to copy 
as closely as possible natural surges and declines in insulin 
levels around and after eating and during the night – see 
Figure 11. Strategies based on subcutaneous injections can 
never fully simulate normal pancreatic action. This is partly 
because the pancreas secretes insulin and related substances 
directly into the hepatic portal vein, which means that the 
hormone becomes available at different concentrations in 
other parts of the body. But from a patient perspective their 
aim is to reduce the long term risks of micro-vascular and 
other forms of damage to a minimum, while also avoiding 
the short term hazard of distressing and potentially life 
threatening ‘hypos’. 
The advent of new products like the insulin analogues, 
coupled with the rising prevalence of diabetes due to factors 
seeking treatment then became focused on being able to 
scale up production safely. 
To overcome this barrier to saving the lives of people with type 
1 diabetes as quickly and efficiently as possible, the University 
of Toronto formed a partnership with Eli Lilly & Company 
in the US to mass produce bovine insulin. Shortly afterwards 
August Krogh founded the Nordisk Insulinlaboratorium in 
Denmark. Following this both the Nordisk Insulin Company 
and the Novo Company (now Novo Nordisk) began pioneering 
insulin production outside North America (Practical Diabetes 
International 2005). In the UK the Medical Research Council 
(which was founded in 1913) was also involved in work on 
insulin from 1922 onwards.
Insulin was first crystallised in what was then thought to 
be a pure protein form in 1926. This opened the way to 
improved production of the hormone from bovine and 
porcine pancreases. In the 1930s longer acting insulins, 
complexed with zinc and protamine (a protein derived from 
fish) were marketed, and after the Second World War products 
such as Neutral Protamine Hagedorn (NPH insulin) gave 
people with type 1 diabetes a further improved chance of a 
good quality of life. Even so, some users developed immune 
responses to insulin derived from animal organs. There were 
also concerns about maintaining supply levels, given that 
the rising incidence and prevalence of diabetes was by then 
starting to become apparent. Outside the industrialised world 
insulin was at best inconsistently available, as is still so today 
in some areas.
After pioneering work by the then newly formed bio-
engineering company Genentech in the late 1970s, it 
became possible to manufacture human insulin on a large 
scale. Products based on the latter from that time onwards 
started to replace animal derived insulin. These appear to 
have brought advantages for many people – not least from 
a supply sustainability perspective – although the extent of 
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such as improved life expectancy, has, as Box 8 discusses, 
caused concern about treatment cost increases in the UK and 
other health care systems. It has been argued, for example, 
by German analysts that there is no evidence that the use of 
rapid acting insulin analogues produces medical benefit, at 
least as defined by recorded HbA1c levels (IQWiG 2006). 
But against this a proportion of people with diabetes who 
have experienced the alternatives now available (including 
people with diabetes interviewed during the preparation 
of this paper) express a preference for analogue insulin 
based regimens. Their personal experience is that the use of 
both long and short rapid acting insulin products provides 
enhanced confidence and improved control. Further, recent 
research suggests that in practice there may in fact be 
significant clinical gains associated with the use of analogue 
based insulins that are only now becoming more fully 
understood. 
For example, Hutchison et al (2008) used the General Practice 
Research Database to compare the occurrence of serious 
hypoglycaemic events in new adult users of human as opposed 
to analogue insulins with type 2 diabetes. They found a 28 
per cent reduction in the occurrence of such incidents in 
the population using analogue insulins as compared with 
those using unmodified human insulin. This is equivalent to 
about one event less per year for every 50 patients treated (de 
Vries 2008). Those responsible for health service resource use 
management may question the value of such gains, or argue 
that they could (in theory, at least) be achieved more cheaply 
via a careful use of older insulins. But this is not necessarily 
consistent with a patient centred approach, or one which 
values in a fully informed way pharmaceutical innovation 
as an investment in the future. 
It would be beyond the scope of this report to analyse this or 
related issues in greater depth, although a brief discussion of 
the wider economics of diabetes care is offered in the following 
section. However, there are to conclude here a number of 
other aspects of insulin use that are presently controversial 
and deserving of special attention. Examples include:
The support needs of children and young adults using insulin 
therapy
The management of (normally type 1) diabetes in children 
and young people is significantly more complex than it 
is for adults (Department of Health Diabetes Policy Team 
2007). Often parents play a large and valuable part in the 
care provided, but this is not always the case. Furthermore, 
in settings such as school life children may have to monitor 
their own glucose levels and administer injections without 
adult help (Newbould et al 2007). 
Young people’s insulin requirements change as they develop. 
It is important that insulin regimens are flexible and 
monitored by competent health professionals. Adolescence 
is often a particularly challenging period, during which the 
rate at which insulin is absorbed in the body can change 
rapidly and without warning. At the same time individuals 
are likely to be undergoing emotional challenges associated 
with becoming independent. This can on occasions lead them 
to reject treatments and advice.
In the UK the quality of care for young people with diabetes 
appears to have lagged behind the standard achieved in 
many other European countries. Relative to its population, 
this country has amongst the highest numbers of children 
with diagnosed type 1 diabetes in Europe. Yet it also seems 
to have a relatively low proportion attaining good diabetes 
control (Department of Health Diabetes Policy Team 2007). 
This suggests a need for further service improvement and 
closer attention to issues such as how specialist physicians and 
other members of dedicated clinical teams can most effectively 
work to support children and young people in their daily lives. 
Where necessary this ought to involve further improving the 
skills of non-specialist health service and other staff. It seems 
likely that an improved NHS supply of items such as insulin 
pumps would help a proportion of young people achieve 
better treatment outcomes.
Insulin delivery systems
The subcutaneous injection of insulin is an essential treatment 
for most people with type 1 diabetes. It is also vital for a 
minority of individuals with type 2 diabetes.4 The provision of 
sophisticated injection devices such as ‘insulin pens’ (which in 
the US tend not to be funded by insurers, and hence are not as 
Box 8. The Cost and Value of Medicines for 
People with Diabetes
The combination of increasing numbers of people being 
identified as having diabetes, more intensive treatments and 
a wider range of therapies has led to raised NHS prescribing 
costs. A recent NHS analysis highlighted the fact that in 
England the number of prescription items supplied to treat 
diabetes rose to over 28 million in 2006. They cost some 
£560 million (The Information Centre and YHPHO 2007). This 
it was stressed was almost 14 per cent above the previous 
year’s figure.
Just over 40 per cent of the total spent was accounted for by 
insulins. They typically cost from 30 pence to up to £1 per 
treatment day. This compares with treatment costs of 10-40 
pence per day for various formulations of metformin, and 
approaching £2 per day for products such as glitazones and 
the incretin mimetic exanitide. It was noted in the context 
of insulins that doctors are increasingly prescribing short 
and long acting analogue products, as opposed to older 
insulins.
However, this does not mean that value for money was not 
obtained from these outlays. The total cost figure quoted 
above was equivalent to about 7 per cent of total prescribing 
expenditure for that year. This is in line with the proportion 
of overall NHS resources spent on diabetes. It is also relevant 
to note that total (all forms of medicine) pharmaceutical costs 
expressed as a proportion of total NHS spending have fallen in 
recent years, and now stand at a level similar to that recorded 
in 1968 (OHE 2008). Yet few would argue that the relative 
productivity of medicines use did not increase in that period. 
NHS and other health care resources should not be wasted. But 
from the viewpoint of people in need of effective treatment 
for their diabetes, emotive or misleading presentations aimed 
selectively at curbing pharmaceutical spending as a factor 
within health care should not be permitted to undermine 
public understanding of the value of the medicines used to 
treat this serious, life threatening, illness.
4  The point at which individuals with deteriorating type 2 diabetes 
should start using insulin is a matter of consumer and clinical 
judgement. Some people may wish to put off this decision for as 
long as possible. But if using insulin helps subjects to improve their 
glycaemic control and is not experienced as a ‘defeat’ or diminution 
in the quality of life, starting it earlier rather than later could help 
reduce subsequent risks.
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widely employed as in Europe) helps insulin users to take correct 
doses. Modern techniques can also minimise any discomfort 
associated with injecting. But using insulin via injection may 
still sometimes cause local pain and itching. Lipodystrophies 
(adipose tissue ‘lumps’ that form under the skin after repeated 
injections) can also occur. These may understandably be 
unwanted cosmetically, can affect insulin absorption, and are 
not always avoidable via injection site rotation. 
The use of new injection systems can sometimes be 
problematic for other reasons. Differences between the 
functioning of devices can on occasions result in problems 
such as recurrent ketoacidosis, if patients using them have 
been inadequately supported in relation to understanding 
appropriate injection techniques (Bhardwaj et al 2006). Such 
instances underline the value of specialist knowledge and 
expertise in the context of diabetes care.
Awareness of the limitations of injection based insulin 
regimens has led to research in a range of areas, from attempts 
to develop insulin ‘patches’ to the formulation of inhaled and 
orally active forms of insulin and the postulated development 
of implantable ‘artificial pancreases’. However, the most 
important option to highlight here is that of insulin pump 
treatment. This form of delivery is widely used in the US 
(where insurance companies typically will fund its use) and 
the wealthier parts of Western Europe but has been much 
less widely available – primarily because of cost restraints – 
to NHS patients. 
In 2004 insulin pumps were endorsed by NICE, but only for 
treating people with specific problems with the injection of 
insulin. A report published in 2007 by the Department of 
Health in association with Diabetes UK (DoH 2007a) noted 
that only about one per cent (or less in the case of children) 
of British people with type 1 diabetes use insulin pumps for 
the routine management of their condition. The equivalent 
proportions in countries such as France, Sweden, Holland, 
Germany and the US are in the range of 10-20 per cent.
Insulin pump usage can for some people with diabetes lead 
to marked improvements in the quality of their life and 
outcome indicators such as HbA1c levels. Nevertheless, it 
requires commitment. Patients need training, and must be 
able to actively manage their glucose levels via testing and 
insulin dose adjustment. Some people find this difficult. 
Perhaps the most frequent concern in this field relates to 
the fact that ketoacidosis may develop quickly if there is a 
fault with the pump, albeit that technical improvements 
have greatly reduced the possibility of the latter since such 
products were first introduced.
Self monitoring of blood glucose levels
The daily management of diabetes involves the effective co-
ordination of diet and energy consumption. For individuals 
requiring insulin treatment the regular measurement of blood 
glucose levels enables them to monitor their condition, and 
amend their insulin use as necessary. But the discomfort 
associated with blood sugar testing can be experienced as 
being much greater than that of injecting insulin or other 
treatments. Amongst the wider population with type 2 
diabetes who are on anti-hyperglycaemic treatment regimens 
without insulin the benefits of blood glucose level self 
monitoring have been much disputed. 
A health technology assessment published in 2000 (at which 
time in the order of £90 million was being spent on glucose 
testing strips annually) concluded that in type 2 diabetes 
there was insufficient evidence to support recommendations 
for self-monitoring. Research undertaken at around that time 
indicated that such testing could undermine quality of life 
(Franciosi et al 2001). In response some PCTs restricted their 
supply of blood glucose testing strips.
More recent studies have reported uncertainties about the 
value of self monitoring in the minds of type 2 diabetes 
patients and clinicians alike (Peel et al 2007) and a lack of effect 
in improving glycaemic control amongst subjects with the 
non-insulin treated condition (Farmer et al 2007). In overall 
terms glucose self monitoring, at least in subjects with type 
2 diabetes who are not on insulin and have not been given 
effective help in using productively the results, appears to be 
associated with raised costs, increased mental discomfort and 
no clinical benefit (Simon et al 2008: O’Kane et al 2008). 
However, some specialists and patient representatives still 
argue that there should be flexibility sufficient to allow those 
individuals with an interest in controlling their condition 
as effectively as possible to monitor their performance. In 
common sense terms it is only to be expected that individuals 
who have not been supported in learning how to respond 
effectively to the information derived from blood glucose 
testing should feel disempowered and depressed by it, 
especially as many people find it painful. 
Studies of forearm testing indicate that this may be less 
painful (Greenhalgh et al 2002), although it can also be less 
accurate and is probably best used at times when a subject’s 
blood glucose is likely to be relatively stable (Ellison et al 
2002). Attempts have in the past been made to develop 
non-invasive devices to facilitate pain free blood sampling, 
although with limited success. Increased attention is currently 
focused on implantable blood glucose monitoring devices, 
which even if they have to be re-inserted on a regular basis 
can offer important benefits.5
Surgical interventions relevant to insulin use
These encompass pancreatic cell islet transplantation for 
individuals with type 1 diabetes, and bariatric surgery (or 
‘stomach stapling’) for obese people with type 2 diabetes. 
Initial attempts at the former were undertaken in animal 
models in the 1960s and in humans in the 1970s. Pancreatic 
tissue transplantation today typically involves the use of 
islet cells isolated from the pancreas of a dead donor. The 
‘Edmonton protocol’, developed in Canada in the late 1990s, 
involves such material being injected into the liver. There 
the cells transplanted may start to monitor glucose levels 
and produce insulin. 
This can, when successful, stop or reduce the need for insulin 
treatment. But transplanted islet cells at best normally survive 
for only a few years, during which time recipients need constant, 
costly and to a significant degree hazardous immunosuppressive 
treatment. NICE guidance issued in 2003 argued that the safety 
and efficacy data then available did not support routine use of 
the procedure except by special arrangement for ‘consent and 
for audit or research’. Although the potential of this technology 
to confer future benefit should not be ignored, it cannot at this 
stage be considered a viable way of treating at a population level 
type 1 or other forms of diabetes.
5  When and if non-invasive or minimally invasive glucose monitoring 
can reliably produce accurate readings its potential to improve 
diabetes care should not be ignored.  Nor should not the utility of 
appropriately employed urine tests be under-estimated. Continuous 
Glucose Monitoring (CGMS) is a method of following blood glucose 
over time, which may offer the prospect of enhanced glycaemic 
control. However, there is little evidence as yet of this leading to 
HbA1c reductions.
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Related options include total pancreatic transplants, as well 
as new forms of pancreatic islet allogenic and, in theory at 
least, embryonic or autologous stem cell derived islet cell 
transplants. However, the capacity of the latter to synthesise 
insulin adequately has not yet been demonstrated, and the 
supply of suitable donor pancreases is limited.
By contrast, there is much more robust evidence as to the 
benefits of bariatric surgery for obese patients with type 
2 diabetes. The surgical procedures used in this context 
involve reducing the functional size of the stomach and small 
intestine via stapling and by-passing. It has been claimed that 
in approaching 80 per cent of patients who undergo such 
surgery diabetes related symptoms will start to be relieved 
within days, even before weight loss has occurred (Swansea 
University 2008). Such apparently dramatic success has led 
some observers to suggest that bariatric surgery has as yet 
unidentified impacts on factors such as the production of 
GLP-1 or perhaps other peptides in the gastro-intestinal tract, 
in addition to its more obvious effect on food intake.
Improving Outcomes 
Since the initial publication of the National Service Framework 
for Diabetes (Box 9) in 2001 there has been considerable effort 
to improve local services. This has been backed by guidance 
from central resources such as the National Diabetes Support 
Team relating to virtually every aspect of NHS diabetes care 
commissioning and delivery. (See, for example, Department of 
Health 2002, 2004, 2007a, 2007b, 2007c.) There has also been 
complementary NHS progress in areas like the prevention and 
treatment of coronary heart and renal disease and long term 
condition management. 
Public agencies ranging from NICE to the MRC (MRC 2002) 
have made additional contributions to diabetes research and 
service development, as have voluntary sector organisations 
such as Diabetes UK and academic and other institutions. 
Even more importantly, the introduction of the Quality and 
Outcomes Framework as a central element in the 2004 GP 
contract has been an effective driver of substantive changes 
in primary care activity. It is to be hoped that the recent 
pharmacy White Paper Pharmacy in England (Cmnd 7341) 
proposals relating to areas such as risk factor identification and 
case finding through health checks and enhanced medicines 
management will also open the way to changes in practice 
standards and service provision. 
It would be beyond the scope of this analysis to attempt to 
critique such developments. But in essence the process of 
change underway is intended to facilitate the establishment of a 
coherently organised, quality oriented, conveniently accessible 
system of diabetes identification and professional treatment, 
coupled with a pro-active approach to self care. The scale of the 
progress already achieved may be illustrated by the fact that in 
England the number of people with diagnosed diabetes doubled 
between 1998 and 2008. Amongst people presently diagnosed 
with diabetes the available local data indicate that, even in 
relatively disadvantaged inner city areas (see, example, Figure 
12), around 70 per cent have their ‘key indicator’ information 
entered in their primary care records. Approaching half appear 
to have an HbA1c level of under 7.5 per cent.
The strong growth in both diabetes occurrence and awareness 
has had important health service work load implications, 
especially as the intensity of the treatments given to people 
with diabetes has also increased. Key strategic questions 
relevant to achieving continued progress include:
1 As the number of individuals at risk of or with 
‘pre-diabetes’ and type 2 increases, how can health 
behaviour changes relevant to preventing the 
condition (or when necessary living with it well) best 
be encouraged?
2 What more might be done from a biomedical 
perspective to either reverse ‘early stage’ type 2 
diabetes, or prevent it from progressing and causing 
harm? 
3 What in future can be done to address the increasing 
incidence of type 1 diabetes, in order to prevent it or 
offer children and young people affected by it with a 
functional cure?
4 What further developments in the medical treatment 
of people with type 2 diabetes might prove most 
significant in the coming ten to twenty years?
Box 9. The National Service Framework for 
Diabetes
The 2001 National Service Framework set out twelve 
standards to ensure good quality care for those with diabetes. 
The areas they cover include:
•	 The	prevention	of	type	2	diabetes
•	 The	identification	of	people	with	diabetes
•	 Supporting	the	empowerment	of	children	and	adults	with	
diabetes, and their efforts to live as healthily as possible
•	 Improving	clinical	care	quality,	and	the	control	of	blood	
glucose levels, blood pressure and other risk factors
•	 Providing	good	quality	care	for	children	and	young	people	
with diabetes, and ensuring that they and their families 
are supported appropriately and a smooth transition from 
paediatric to adult services for young people
•	 Managing	diabetic	emergencies	effectively
•	 Improving	hospital	care
•	 Support	for	women	with	pre-existing	diabetes	and	those	
who develop diabetes during pregnancy
•	 Providing	long	term	condition	support
In 2003 the NSF for diabetes delivery strategy (England) 
described how the twelve standards would be implemented 
(Department of Health 2003). Key components of the strategy 
involve:
•	 Setting	up	local	diabetes	networks	
•	 Reviewing	local	baseline	assessments	
•	 Comparative	local	and	national	audits	
•	 Developing	relevant	workforce	skills	profiles	
•	 Putting	in	place	registers,	education	and	advice,	to	support	
systematic treatment regimes; and
•	 Delivering	a	nationwide	eye-screening	programme.
In this last context, for example, the NSF established a target 
that by 2006 80 per cent of people with diabetes would be 
offered retinal screening. This would rise to 100 per cent at 
the end of 2007. In 2005 Diabetes UK reported that 40 per 
cent of people with diabetes had not been offered screening 
(Diabetes UK 2005). But recent Department of Health figures 
indicate an encouraging improvement in performance (DoH 
2008a).
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Figure 12. Key Diabetes Indicators by Ethniciy – Islington GP Practices
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5 How can optimally productive relationships between 
specialist and generalist medical care, and between GP 
practice based primary health care professionals and 
community pharmacy, best be achieved? 
6 What economic, social or other barriers to health 
improvement and successful pharmaceutical 
innovation must be overcome in order to deliver future 
progress?
Promoting healthy behaviours and effective 
self care
The experience of countries such as Finland in heart disease 
and diabetes suggests that further progress towards primary 
prevention will be possible in this country. A combination 
of interventions aimed at, for instance increasing the relative 
price of ‘fast foods’, coupled with:
•	 mass	communication	approaches	such	as	Diabetes	UK’s	
‘measure up’ campaign;
•	 targeted	local	interventions	like	workplace	initiatives	
on diet and exercise; and 
•	 individual	advice	and	support	delivered	in	settings	
such as surgeries and pharmacies
has the potential to change significantly not only individual 
thinking, but eventually the wider social context in which 
personal decisions are taken (Taylor et al 2006). 
However, the time required to achieve this end and the 
extent of the resistance likely to be encountered – especially, 
perhaps, amongst those most at risk from premature death or 
disability from diabetes – ought not to be under-estimated. 
In the parallel field of smoking prevention and cessation 
support it took half a century to achieve today’s acceptance 
of the need for effective action. Further, there now appears 
to be a ‘hard core’ of relatively vulnerable population groups 
that remain most likely to start smoking, and to become 
nicotine dependent. Similar patterns could in future more 
clearly emerge in relation to obesity and type 2 diabetes in 
the UK. 
With regard to tobacco smoking, the Royal College of 
Physicians (2007) has recently argued that it would be in the 
interest of those who are least able to stop to offer them the 
alternative of long term therapeutic nicotine (NRT) use. This 
could (through substitution) prevent their addiction leading 
to avoidable harm. 
Similarly, looking forward to enhancing the future outcomes 
of diabetes care, the view taken here is that when and if there 
is evidence that pharmaceutical use can (after taking into 
account all likely costs) augment the effects of behaviour 
change programmes, or protect individuals who do not 
choose to alter their lifestyles, constructive attention should 
be paid ensuring the fullest possible population access to 
relevant products. This could include not only enhancing the 
provision of blood pressure and cholesterol lowering agents, 
but also present (or possible future) medicines that might 
safely be used for reducing obesity levels and/or normalising 
glucose metabolism early on in the development of insulin 
resistance and pancreatic damage.
However, the impact of such strategies can only be optimised 
if they are successfully linked to progressively more effective 
means of changing related health behaviour. The latter 
might include the increased use of ‘reward feedbacks’ 
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Box 10. Enhancing Dietary Control – DAFNE 
and DESMOND
The Dosage Adjustment for Normal Eating (DAFNE) course 
consists of a 5 day outpatient program for people with type 
1 diabetes. It teaches flexible intensive insulin treatment 
combining dietary freedom and insulin adjustment, with 
the aim of improving clinical outcomes (glycaemic control) 
and quality of life. A study of 160 adults with type 1 diabetes 
found that 6 months after the DAFNE course HbA1c levels 
were significantly better in those who had completed it. The 
increased dietary freedom with the DAFNE approach led to 
significant improvements in quality of life (DAFNE Study Group 
2002). This is consistent with the experience of individuals 
interviewed during the preparation of this report. Yet although 
their value is relatively well established, UK professionals point 
to problems in funding DAFNE programmes. This contrasts 
with experience in countries such as Germany, where the 
DAFNE course is a routine part of diabetes care.
Diabetes Education and Self- Management for Ongoing 
and Newly Diagnosed (DESMOND) is for men and women 
who have been newly diagnosed with type 2 diabetes. It is a 
structured education programme which consists of 6 hours 
of group sessions delivered to a maximum of 10 people by 
a health professional in the community. Recent research 
(Davies et al 2008) indicates that the DESMOND programme 
successfully promotes weight loss and smoking cessation. It 
also supports positive changes in attendees’ beliefs about 
diabetes. Yet a year after diagnosis HbA1c levels were 
unchanged. Observations such as this last might lead to some 
questioning of the value of using HbA1c levels as an indicator 
of diabetes care quality and/or likely outcomes, although this 
is not to say that an uncritical approach should be taken to 
evaluating self care support interventions.
(like ‘instant’ test scores and/or supportive messaging that 
positively reinforce desired behaviours), the structured use 
of behavioural ‘cues’ (such as automated mobile phone 
voice and text ‘reminders’) and the delivery of ‘health 
intention’ formation and implementation programmes via 
the internet and/or in settings like community pharmacies 
(Horne 2008).
In the context of people living with type 2 diabetes there 
is already evidence that (amongst individuals who elect to 
attend them) exercise support programmes can be beneficial. 
(See, for instance, Krousel-Wood et al 2008.) So too can similar 
interventions designed to enable individuals and groups to 
control their diets (Box 10), use medicines effectively and raise 
their sense of self efficacy in relation to managing diabetes. 
The extent of the possible gains to be derived from supporting 
self care should not be overstated (Newbould et al 2006, Taylor 
and Bury 2007). But neither should potentially significant 
opportunities for improving future health outcomes be 
neglected (Newman et al 2004). 
It is therefore of some concern that a survey undertaken by the 
Healthcare Commission in 2006 found that although 40 per 
cent of the total population interviewed would like to attend 
a diabetes self management course, only a tenth of the people 
who were interviewed had done so (Healthcare Commission 
2007). The Commission has since sought to stimulate better 
performance in this area and to help ensure that all GPs 
receive the support they need to manage and monitor the 
care of people with diabetes effectively, where necessary in 
partnership with both specialists and local colleagues such 
as community pharmacists.
Better treatments
From a biomedical perspective, the combination of genetic 
vulnerabilities and external triggers that cause type 1 diabetes 
may in the coming decade or two be sufficiently elucidated 
to allow effective preventive measures to be introduced. 
Failing this, several of the experts consulted for the purpose 
of this analysis believe that more effective strategies will 
demand advances based either on stem cell science and the 
regeneration of lost pancreatic tissue, or the development 
of ‘artificial pancreases’. These will almost certainly involve 
the use of implantable (as distinct from non-invasive) blood 
glucose (and perhaps insulin) level monitoring devices. The 
latter could be used in ‘closed-loop’ configurations with 
insulin pumps that automatically infuse the hormone. 
Alternatively, they will replace existing glucose monitoring 
devices used to support self injection. 
This last opportunity alone might significantly improve 
glucose control, and hence health outcomes, in the overall 
insulin using population. But advocates of ‘artificial pancreas’ 
argue strongly that within five to ten years the impact of this 
technology could be even greater, transforming the lives of 
many insulin users (Hovorka et al 2006). In the light of such 
anticipated advances it might reasonably be argued that NHS 
policy and practice relating to the provision of insulin pumps 
is (over and above the NICE appraisal of existing technology 
presently being developed) in need of review.
Developments that will allow the delivery of the hormone via 
inhalation, or perhaps more importantly orally, should also 
further improve the quality of life for, and hopefully long term 
health outcomes amongst, people with diabetes. One inhaled 
insulin has already been marketed and later withdrawn, world 
wide. This was largely because of the reluctance of health 
service funders to finance its supply, together with other factors. 
Some commentators may question the long term desirability 
of delivering relatively large doses of insulin to the lung. But 
even so, this experience may still be regarded as demonstrating 
the technical viability of inhaled insulin treatment.
Research in this field together with that of developing orally 
administered insulin is continuing, not only in Europe 
and the US but also in India (Gowthamarajan and Kulkani 
2003). Companies working in south Asia are amongst those 
aiming to be the first on the world market with insulin in 
tablet form. Yet for this to be achieved a number of complex 
scientific problems have still to be overcome. The efficiency 
with which oral insulin can be delivered via the intestine into 
the blood stream is presently too low to permit cost effective 
products to be developed. But if this and other challenges 
can be mastered, oral insulins could change radically diabetes 
care. They would make taking insulin much easier. The fact 
that delivering insulin in this manner can be seen as being 
much closer to the natural hepatic portal vein route is another 
potentially relevant factor. 
Otherwise, improving the range of effective anti-diabetic 
medicines available will require further exploration of known 
therapeutic mechanisms, including those responsible for 
the actions of metformin, the glitazones and the incretins, 
together with research in areas such as the actions that 
adipokines have on cells in the muscles, the liver and the 
pancreas. Additional exemplary areas of pharmaceutical 
research include investigating the ways substances such 
as leptin (a protein hormone first identified in the mid 
1990s) ghrelin (a hormone produced in the stomach and 
the pancreas) and peptide YY (PYY) may, together with 
other naturally occurring molecules, act in the brain and 
elsewhere to regulate food intake and glucose metabolism. The 
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development of medicines aimed specifically at preventing 
microvascular disease caused by high blood glucose levels is 
another future possibility.
The ongoing discovery of increasing numbers of diabetes 
related gene variations is also providing pharmaceutical 
scientists with further opportunities to develop new 
treatments and diagnostic tests. It is in this last area that 
innovations derived from recent ‘breakthroughs’ in genomics 
are in the near future perhaps most likely to be marketed. 
Particularly when combined with physical measurements 
such as cholesterol and body mass indices and also 
family history based information, recent developments in 
understanding genetic associations with diabetes could be 
used to offer relatively powerful predictive tests to people such 
as younger working age adults before they develop problems 
such as insulin resistance.
If this were to enable individuals (and families) to make 
more informed lifestyle and treatment choices than would 
otherwise be possible it could generate considerable health 
gain. But some professionals argue that it will be better to go 
on advising everyone to live as ‘healthily’ as possible, rather 
than to permit freer access to more specific personal data. 
It has been suggested that ‘unregulated’ (implicitly, more 
easily accessed) testing could promote needless fears on the 
one hand, or misplaced complacency on the other (Sense 
About Science 2008). However, objections to extending public 
access to diagnostic and allied testing might on occasions 
be linked to vested interests. They could, for instance, stem 
from professional rivalries and concerns that enhanced access 
to home or ‘near patient’ testing in community pharmacies 
might undermine the ‘trading’ position of some other groups 
and institutions.
Barriers to overcome
One critical barrier to improving diabetes care is that of 
insensitivity to the experiences and priorities of people 
living with the condition. On occasions appeals to listen to 
consumer views are dismissed as unscientific, or regarded 
as ‘mere marketing’. Yet such reactions can themselves 
sometimes appear arrogant, and risk failing to address issues 
at the heart of achieving better outcomes. In reality service 
user experiences and preferences frequently provide useful 
insights as to how services could be improved – see Box 11.
Organisations such as pharmaceutical companies, along 
with those that act as the advocates of particular service user 
groups, will naturally wish to encourage the use of effective 
new medicines and other innovative treatments. The global 
market for diabetes treatments has ‘out-performed’ the 
pharmaceutical sector as a whole since the middle of the 
1990s (Hauber and Gale 2006). But it should not be assumed 
that this is undesirable. 
Nor should it be forgotten that individuals responsible for 
functions such as cost control in organisations like those 
responsible for commissioning health services may have 
pressures upon them that sometimes distort their judgements 
in the direction of under-using new treatments. This is a 
particular hazard when it comes to balancing immediate 
cost savings against longer term – and frequently inherently 
difficult to quantify – clinical, psychological and social 
benefits. In contexts where labour costs are difficult to reduce 
outlays on innovative therapies may appear to be the only 
expenditure variable open to adjustment, even if they account 
for only a limited percentage of a total budget.
The DAWN (Diabetes Attitudes, Wishes and Needs) 
programme is an example of a beneficial initiative supported 
by the pharmaceutical industry in partnership with voluntary 
sector bodies and professional groups. It has revealed concerns 
amongst people with diabetes about the extent to which their 
condition interferes with their lifestyle aspirations because of 
the difficulties associated with taking treatments and other 
aspects of the condition. There is no easy answer to the 
challenge of helping individuals, families and communities 
to live as well as possible with diabetes. Often there may be 
complex reasons why apparently simple solutions are not 
viable. But even so there is a strong case for listening openly 
and without any pre-judgement to those affected. Failures 
to do this may lead to the introduction of what appear to 
be managerially viable health care developments, which in 
practice do not work.
At the same time, people with diabetes and members of the 
wider public should strive to develop a critical, science based, 
awareness of the progressive nature of the type 2 condition 
and how it can be prevented or effectively controlled. There is 
evidence, for instance, that only a minority – probably under 
a quarter – of the population has insight into the differing 
aetiologies of types 1 and 2 diabetes. Increased knowledge 
about such matters may not directly enable individuals to 
change their lifestyles. But if the mechanisms by which 
factors such as regular moderate exercise or an increased waist 
size can either stop or promote progression towards type 2 
diabetes are not understood, this could nevertheless impair 
the transmission of health promotion messages.
Some of the pitfalls of improving diabetes related self care 
have been illustrated by research in Scotland. The work 
of Lawton et al (2005) illustrates the power of contextual 
influences on illness perceptions and health behaviours. They 
observed that patients receiving diabetes care from their GPs 
were less likely to regard their condition as ‘serious’ than those 
going to hospital based providers, even when from a medical 
perspective this was not the case. The primary care users were 
consequently less motivated to change their behaviours in 
ways that might protect them from future harm. 
Similar variations may sometimes be associated with taking 
insulin as opposed to oral anti-hyperglycaemic medicines, 
in that the latter may be seen as for ‘less serious’ illness. 
Such findings underline the importance of establishing a 
sensitive awareness of the practical implications of ‘lay’ 
health perceptions, and the paradoxical impacts that well 
intended but poorly researched service developments may 
make on outcomes.
As the diagnosed prevalence of diabetes has increased, so too 
has the importance of devolving the provision of support and 
care to the most conveniently accessible level. The purpose of 
this is not least to ensure that service supply can affordably 
meet demand. The extension of diabetes care (especially in 
relation to the type 2 condition) by GPs and their practice 
based nurse colleagues has been an important trend, which 
in future is likely to continue. Similarly, an extension of 
‘health check’ provisions and ‘pre-diabetes’ life style support 
and treatment provision in community pharmacies should 
also prove beneficial. Yet the benefits and requirements of 
specialist care should not be ignored by commissioners (ABCD 
and Diabetes UK 2008). 
Patient and wider public interests will be best served by 
systematic approaches to ensuring that secondary and tertiary 
care providers complement each other, and are sufficient to 
support the further extension of appropriately integrated 
and (cost) effective primary care for children and adults in 
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the community (Matthews 2007). However, this should not 
necessarily be interpreted as meaning that this demands the 
creation of large, effectively merged, local integrated care 
providers, or that housing specialists and generalists together 
in new buildings is any substitute for constructive values 
and the ‘relationship based’ delivery of seamless care in day 
to day practice. In many instances plural care provision, 
characterised by a pragmatic mix of supported collaboration 
and regulated competition, will be most likely to enhance 
individual and population outcomes.
A final barrier to achieving future therapeutic progress 
relates to the closely related issues of financing of scientific 
innovation and the funding of new treatment options when 
they become available in the market. The establishment of 
bodies such as NICE (the National Institute for Health and 
Clinical Excellence) in England and IQWiG (the Institute for 
Quality and Efficiency in Health Care) in Germany has been 
an important development. In an area as costly and damaging 
to modern society as diabetes (Box 12) few people would argue 
against the logic of seeking to ensure that money spent on all 
forms of service provision – including not only medicines but 
also the far larger amounts devoted to salaries – is allocated 
as wisely as possible. 
Health economic analyses are intended to guide such decision 
making. However, the limitations of the methods used and the 
processes surrounding the work of bodies such as NICE and 
IQWiG deserve attention. From the perspective of people and 
communities at risk from diabetes and the agencies seeking 
to discover and disseminate better means of prevention and 
treatment, examples of relevant concerns include:
•	 lack	of	insight	into	both	personal	and	wider	
community needs. The techniques normally used 
by health economists do not directly involve asking 
people who have experienced given types of illness 
about the details of their experience. Nor do they take 
into account the varying impacts specific illness may 
have on the families of those affected or the wider 
community; 
•	 data	aggregation. Following on from the above, 
pooled figures on the benefits of given types of 
intervention may conceal the fact that some groups 
gain significantly more or less than the average. Bodies 
such as NICE acknowledge this last point, and stress 
that their guidance is typically valid in only about 80 
per cent of cases (Rawlins 2008). But this may not be 
recognised in practice by health care funding agencies 
and local providers;
Box 11. Emma’s Experience with her Insulin Pump
‘I was diagnosed with diabetes 23 years ago and like most diabetics was injecting insulin. About 10 years ago I started to develop 
a stomach problem, I wasn’t digesting my food properly and wasn’t getting the nutrients I needed. My diabetes control started 
to go very wrong, my blood sugars would go up ten hours after eating, not straight after as they should do. My treatment was 
up to 12 injections a day but I could still not get control of my diabetes. At this point control was so bad that I was in and out 
of hospital. I had to give up my job in retail because I was so ill all the time.
For a long time I’d been secretary of the local diabetes group so had heard about insulin pumps. I had thought about having 
a pump before, but it was expensive and I’d just had to give up work. At a diabetes awareness day I met the local pump rep 
and they were doing a one month free trial of the pump. I applied to my PCT for funding for the consumables and, after lots 
of phone calls and a lot of chasing, they agreed to fund them. After the one month I was offered four years interest free credit 
on the pump which was £45 a month.
Once I’d decided I wanted the pump I went to the GP and to see my diabetes doctor at the hospital. The hospital doctor said 
to me ‘well Emma it sounds a bit drastic’ and I said to him ‘well I feel that having to give up work and being in hospital every 
other week – that is drastic!’. I also had to get the support of a diabetes specialist nurse who would back me. I was really lucky 
in that one of the diabetes nurses had a son who had diabetes and because of that she took a weeks holiday and paid for the 
course herself, the PCT would not pay for that. PCTs not paying for the specialist training is a stumbling block to people being 
able to use pumps. I’ve met consultants who would like more people to be on pumps but the staff are not trained to provide 
the support needed.
So I eventually got the pump for the free trial and I instantly got on with it. You have to do a training session which you have to 
pay for. The training day was a Thursday and a Friday and on the Friday night the rep called me to ask how I was getting on – I 
told him he was never getting the pump back! The change was so quick I could hardly believe it. I instantly felt better and in 
about the next 3-4 weeks I felt like nothing was wrong with me. I had been off work for a year by this time but once I was on 
the pump I was back in a job a week later – it really was that quick. Since I’ve had the pump I’ve not been in hospital at all and 
as I say before then I was in every other week.
The pump does have some maintenance but it is nothing like the injections. You have to change the needle in your stomach 
every 2-3 days and change the canula every 5 days. You do have to do a lot of blood testing – for people who hate them it’s not 
the right treatment for them. I do a minimum of 2 a day but if I’m cold or unwell then I might do at the most 12 a day.
I occasionally catch the tubing which gives you a bit of a twinge. But you can disconnect it for short periods, like when I go for 
a swim or when I go for a shower.
I finished paying for the pump in October and on 2nd November the pump suddenly wasn’t working. I phoned the company 
to ask what was going on and they said I needed a new one. I couldn’t believe it – I had no idea it would wear out! I had to go 
back onto injections and my control was worse straight away. I felt like death for 2-3 days. Luckily by this point the PCT was 
funding them and within 7 days I was back on a pump and back to normal. It was a horrible reminder of what my life was like 
before I had the pump.’
Source: School of Pharmacy research
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Box 12. The Economics of Diabetes Prevention and Treatment and NICE’s Work
The economic burden imposed by diabetes, and the costs and benefits of its treatment, have been extensively reviewed – see, for 
instance, Raikou and MaGuire (2003) and Williams (2005). Diabetes is responsible for between 5 and 10 per cent of all premature 
mortality and disability in countries such as the UK and in the order of 7 per cent of all health care expenditure. The available 
research emphasises the impact of macro and micro vascular diabetic complications on hospital care costs, albeit that for many 
people the latter are not as important as the less tangible personal distress and loss diabetes causes.
Trials such as the UKPDS have provided economic data supporting the use of medicines such as metformin and captopril (an 
antihypertensive). However, the detailed components of such calculations may change over time, not least as pharmaceutical 
and other factor costs alter. Further, the introduction and enhanced use of treatments such as statins in the context of reducing 
diabetes related macrovascular morbidity and mortality may over time change the relative costs and benefits of other interventions 
used in the field. The view taken here is that it is in fact impossible to calculate with any degree of precision the likely future 
benefits of innovations such as, say, the vascular disease screening programme recently proposed by the Department of Health, 
or those which might in future stem from innovations like the introduction of oral insulins. But this is no reason for failing to 
support progress in such areas if there is a realistic possibility of it leading to enhanced welfare.
This conclusion suggests that there as a danger that the work of organisations such as NICE could unwittingly promote a false 
sense of certainty about decision making for the future. In the decade or so that is has existed NICE has produced about a dozen 
guidelines and appraisals relevant to diabetes care. Several more are in development. Even so, there has recently been concern 
that some medicines will be unfairly ‘blighted’ by the lack of an appropriate NICE analysis. In an attempt to address this problem 
the agency is seeking new approaches to providing rapid guidance.
Some commentators fear that the ‘short clinical guideline’ solution being developed could foster a new set of problems. However, 
at a more general level a deeper problem is that few people – including politicians, journalists, service managers, doctors and 
pharmacists – have adequate insight into what techniques such as incremental cost utility analysis (NICE’s central analytical 
instrument) involve, or what statements suggesting that a given treatment delivers benefits costing more or less than the rough 
affordability threshold of £30,000 per quality adjusted life year (QALY) really mean. 
The following simplified example may illustrate the types of point that need better to be understood:
•	 A	patented	medicine	(A)	used	to	protect	against	diabetes	related	risks	costs	£600	a	patient	year,	and	delivers	on	average	22	
QALYs per 100 people treated per year. The cost per QALY is therefore £600x100/22 = £2727. 
•	 A	new	medicine	(B)	becomes	available	at	£650	a	year.	It	protects	against	the	same	risks	and	generates	23	QALYs	per	100	
people treated, at a cost per QALY of £650x100/23 = £2826. 
•	 The	average	cost	per	QALY	difference	is	circa	£100.	The	incremental	cost	utility	of	the	new	medicine	(B)	against	the	older	
less effective A (ie the cost per extra QALY gained) is £5,000 (£650 x100 – £600 x 100). This is well within the £30,000 
threshold.
•	 However,	the	original	medicine’s	patent	ends	and	the	price	falls	 to	£100	per	patient	year.	The	 incremental	cost	utility	of	
medicine B against A therefore rises to £55,000 (£650x100 – £100x100). This is well above the assumed NICE affordability 
threshold.
This means, all other things remaining constant, not only that medicine B becomes unaffordable and that NHS patients who 
would benefit from its use become unable to do so. It also suggests that in this specific area no new patented medicine with extra 
benefits of a magnitude comparable to that generated by medicine B will be supplied by the NHS. If other health care systems 
were to follow suit, research on this area of diabetes care would have to stop. 
•	 evaluation	delays. The collection of evidence 
required for large scale evaluations may require a long 
period of time. This means that regulators’ judgements 
often lag behind informed clinical opinion. This can 
create delays in the achievement of appropriate public 
access to treatments. Such problems are exacerbated if 
evaluations fail to consider all the therapeutic options 
available at a given point of time (Box 12) or cannot 
be updated flexibly when new products or bodies of 
evidence become available; and 
•	 uncertainties about what in reality is 
affordable	coupled	with	failures	to	consider	
long term public interests. Setting affordability 
thresholds in contexts such as NHS care can be seen 
as a relatively arbitrary process, particularly when it is 
remembered that established interventions involving 
high labour costs are unlikely to subjected to the same 
scrutiny as new treatments. Agencies such as NICE are 
charged with making essentially short term decisions 
about the provision of fragmented ‘items of treatment’, 
rather than integrated strategic judgements about 
care delivery and issues such as the future value of the 
research based pharmaceutical industry to Britain, the 
EU and the world as a whole.
Although individual innovations may be of varying utility, 
sustained investment in fields such as diabetes are needed 
over decades to allow the full value of long term discovery 
processes to be realised. In a sense the therapeutic revolution 
started by Banting and his colleagues is still in progress. It 
is not necessarily in the public’s interest to treat medicines 
as ‘one-off’ items to be evaluated in isolation, rather than as 
linked steps along a continuing funding path towards finding 
better treatments for diabetes.
The above points should not be taken to imply that the 
work of agencies such as NICE and IQWiG lacks any value. 
But they highlight the fact that, at both the political and 
personal levels, deciding whether or not to supply or use 
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products such as insulin analogues or other new medicines is 
a complex process. The overall public interest is much harder 
to identify than is sometimes assumed. In addition, clinical 
and service user opinions and preferences are still needed 
to identify the best way forward in individual cases. Broad 
brush evaluations and guidelines should logically be seen 
as offering a framework for informing clinical and personal 
choice, rather than its curtailment. 
Conclusion 
Diabetes directly affects the lives of some three million people 
in the UK, together with those of family members and others 
whose roles include caring for people who have been disabled 
by the condition. Worldwide the equivalent figure is 200 
million, and this is forecast on the basis of established trends 
to rise to about twice that number in the next two decades. 
This trend is in large part explained by predicted prevalence 
rises in Asia and Africa. 
As the twenty first century proceeds diabetes is almost 
certain – failing a mass return to pre-industrial age living 
standards – to affect an even greater proportion of humanity 
as it collectively ages and if, as presently seems likely, obesity 
rates continue to climb. Yet alongside there is today a much 
stronger scientific, professional and political understanding 
of the causes and possible means of preventing diabetes than 
has ever before existed. To the extent that this is successfully 
translated into protective life style changes and better 
therapies, this report’s analysis suggests that the rising rates 
of diabetes will eventually be curbed. 
In retrospect, the current diabetes pandemic might then 
become regarded as part of a positive transition towards a 
healthier world. But it would be rash to suggest that such 
progress is inevitable, and attention should not be drawn 
away from the current levels of suffering inflicted by diabetes. 
There is some evidence that in the US population, for 
instance, glycaemic control amongst the diabetic population 
may have failed to have improved in line with the potential 
of better treatments (Koro et al 2004). Further, better medical 
recognition of diabetes related risks amongst men could to 
a degree have been offset by an increase in diabetes linked 
mortality and disability in women. 
Effective action to reduce the threat of diabetes therefore 
remains an urgent priority across the globe. In this country 
initiatives such as those associated with the 2004 GP contract’s 
QOF have led to important service improvements. They are 
allowing the benefits of pharmaceutical and other therapeutic 
advances to be more widely enjoyed. Agencies such as NICE 
and (in England) the Department of Health are also investing 
in understanding health behaviours relating to the ‘metabolic 
syndrome’, and how they can be changed.
From the perspective of this study it is also relevant that 
professions such as pharmacy are adapting to meet twenty 
first century health care needs. Community pharmacists 
are beginning to focus more of their working effort on 
supporting effective medicine taking for long term conditions 
like diabetes, and enhancing their wider health promotion 
competencies. This offers a prospect of significant additional 
gains, particularly if the progress achieved to date is effectively 
supported by:
•	 ‘world	class’	service	commissioning, which 
through the intelligent direction of funding 
incentivises and facilitates the improvement of health 
outcomes. In the community pharmacy context the 
introduction in England of ‘directed enhanced’ services 
(which PCTs, when a need has been identified, will be 
obliged to fund) could prove valuable in ‘kick starting’ 
further service developments. But in the longer term 
this may be no substitute for better informed local 
level service development processes;
•	 integrated	remuneration	strategies, which will 
encourage professionals like GPs and community 
pharmacists and also specialist and generalist care 
providers to work together to provide seamless care 
when this is needed but which do not eliminate 
‘healthy’ competition or lead to the formation of 
needlessly large organisations which service users may 
experience as denying them local choice;
•	 enhanced	access	to	self	help	and	‘therapeutic	
education’ groups and resources, where there is 
evidence that this can effectively promote desirable 
life style changes, better medicines taking and/or other 
positive gains; and
•	 the	further	establishment	of	an	open,	
listening, culture which values understanding 
service user experiences and the ways in which 
each individual’s life quality can most effectively be 
improved.
However, even if such advances are achieved and existing 
social and scientific knowledge is used to the full, this will 
not fully solve the problem that diabetes represents. This 
is in part because a significant proportion of diabetes cases 
are not attributable to modifiable factors. It is also because 
mass behavioural change is unlikely to be rapidly achievable, 
especially among less advantaged groups located within rich 
societies. Given such realties, the continued improvement of 
bio-medical treatments for diabetes has a vital part to play 
in further improving outcomes in terms of both primary 
and secondary prevention. That is, in preventing diabetes 
from becoming manifest wherever possible, and treating it 
effectively whenever necessary. 
In the medium to long term, advances in areas such as 
genetics, immunology and stem cell research could make it 
possible effectively to eradicate all forms diabetes through, for 
instance, preventing beta cell destruction and/or promoting 
pancreatic regeneration. In the shorter term advances in fields 
such as ‘artificial pancreas’ technology and better glucose 
monitoring, the development and marketing of easy-to-
take forms of insulin and other more effective medicines, 
and diabetes risk testing all promise significant, realistically 
achievable, progress. 
It is reasonable to conclude, therefore, that although the scale 
and gravity of the challenge that diabetes presents to modern 
humanity is comparable to that of any past plague, it can and 
will be overcome if societies are prepared to invest adequately 
in both the research needed to develop pharmaceutical and 
allied innovations, and the health care and wider welfare 
systems needed to deliver them well. In the final analysis 
‘beating diabetes’ will not be a matter of biomedical advance 
on the one hand or social intervention on the other. Rather, 
relevant public health improvement in the twenty first 
century will demand an effective, balanced, combination of 
the two. Modern pharmacists have an important opportunity 
to deliver such an amalgam though supplying medicines, 
enhancing their clinical use and promoting individual and 
wider community learning and change.
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5Diabetes:  
A chronic disease where blood
glucose is too high, either
because insulin is not produced
or is insufficient
Symptoms: 
Tiredness, weight loss, increased
thirst, passing a lot of urine,
blurred vision
Complications: 
Serious complications can result
from elevated blood glucose,
some of which are illustrated here.
However these are largely
preventable, and can be delayed
with early diagnosis and effective
treatment
Effective
treatment
can reduce
costly diabetes
complications
by up to 50%
Heart Attack
Risk:
Increased by 300%, and
heart disease is up to
4 times as likely
Effective treatment:
Leads to a reduction in
heart failure of over 50%
Stroke
Risk:
Up to 4 times as likely
Effective treatment:
Reduces strokes by more
than a third
Amputation
Risk:
15% develop foot ulcers
and up to 15% of these need
amputations. Most common
cause of non-traumatic
lower-limb amputations
Effective treatment:
Reduces the number of
amputations and effective
education reduces the
number of foot ulcers
Total Kidney Failure
Risk:
3 times as likely as in the
normal population. About
30% of type 2 patients have
renal disease
Effective treatment:
Reduces the causes of kidney
failure by more than a third
Blindness
Risk:
Single largest cause of new
cases of adult blindness in
the UK.  Nearly all those with
type 1 diabetes experience
minor retinal damage within
20 years, as do 60% of those
with type 2
Effective treatment:
Reduces serious deterioration
by more than a third
Figure 1 | Effective treatment can reduce costly diabetes complications by up to 50%
Sources: UKPDS (5, 6) and National Diabetes Audit (7)
Effective treatment can reduce costly diabetes complications by up to 50%
Source: Diabetes: finding excellence? The MODEL group.
Living with Plenty – Meeting the Challenge of Diabetes was 
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of London, are committed to working with people with 
diabetes and partners in the NHS and elsewhere to enhance 
the prevention and treatment of this and other conditions. 
The primary objectives of this report are to promote the 
further development of pharmacy based care as a cost 
effective part of the support available to people with 
diabetes and to highlight the importance of pharmaceutical 
innovation alongside that of facilitating relevant forms of 
health behaviour change.
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